WO1997046556A1 - OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY - Google Patents

OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Download PDF

Info

Publication number
WO1997046556A1
WO1997046556A1 PCT/US1997/009536 US9709536W WO9746556A1 WO 1997046556 A1 WO1997046556 A1 WO 1997046556A1 US 9709536 W US9709536 W US 9709536W WO 9746556 A1 WO9746556 A1 WO 9746556A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
hydroxy
oxadiazol
phenyl
amino
Prior art date
Application number
PCT/US1997/009536
Other languages
French (fr)
Inventor
Tesfaye Biftu
Danqing Dennis Feng
Michael H. Fisher
Chan-Hwa Kuo
Gui-Bai Liang
Ann E. Weber
Elizabeth M. Naylor
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614191.6A external-priority patent/GB9614191D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to EP97929769A priority Critical patent/EP0906310A4/en
Priority to JP10500782A priority patent/JP2000511903A/en
Priority to AU33748/97A priority patent/AU712057B2/en
Publication of WO1997046556A1 publication Critical patent/WO1997046556A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Oxadiazole substituted benzenesulfonamides are selective β3 adrenergic receptor agonists with very little β1 and β2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduce neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

Description

TITLE OF THE INVENTION
OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
CROSS REFERENCE TO RELATED APPLICATIONS
This application is based on, and claims priority from, provisional application 60/019,295 filed on June 7, 1996.
BACKGROUND OF THE INVENTION β-Adrenoceptors have been subclassified as βi and β2 since 1967. Increased heart rate is the primary consequence of βl- receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from β2 stimulation. Adipocyte lipolysis was initially thought to be solely a βl -mediated process. However, more recent results indicate that the receptor-mediating lipolysis is atypical in nature. These atypical receptors, later called β3- adrenoceptors, are found on the cell surface of both white and brown adipocytes where their stimulation promotes both lipolysis (breakdown of fat) and energy expenditure.
Early developments in this area produced compounds with greater agonist activity for the stimulation of lipolysis (β3 activity) than for stimulation of atrial rate (βl) and tracheal relaxation (β2). These early developments disclosed in Ainsworth et aL, U.S. Patents 4,478,849 and 4,396,627, were derivatives of phenylethanolamines.
Such selectivity for β3-adrenoceptors could make compounds of this type potentially useful as antiobesity agents. In addition, these compounds have been reported to show antihyperglycemic effects in animal models of non-insulin- dependent diabetes mellitus.
A major drawback in treatment of chronic diseases with β3 agonists is the potential for stimulation of other β-receptors and subsequent side effects. The most likely of these include muscle tremor (β2) and increased heart rate (βl). Although these phenylethanolamine derivatives do possess some β3 selectivity, side effects of this type have been observed in human volunteers. It is reasonable to expect that these side effects resulted from partial βl and/or β2 agonism.
More recent developments in this area are disclosed in Ains worth et al., U.S. Patent 5,153,210, Caulkett et al., U.S. Patent 4,999,377, Alig et aL, U.S. Patent 5,017,619, Lecount et aL, European Patent 427480 and Bloom et aL, European Patent 455006.
Even though these more recent developments purport to describe compounds with greater β3 selectivity over the βl and β2 activities, this selectivity was determined using rodents, in particular, rats as the test animal. Because even the most highly selective compounds, as determined by these assays, still show signs of side effects due to residual βl and β2 agonist activity when the compounds are tested in humans, it has become apparent that the rodent is not a good model for predicting human β3 selectivity. Recently, assays have been developed which more accurately predict the effects that can be expected in humans. These assays utilize cloned human β3 receptors which have been expressed in Chinese hamster ovary cells. See Emorine et al, Science. 1989, 245:1118-1121 ; and Liggett, Mol. Pharmacol.. 1992, 42:634-637. The agonist and antagonist effects of the various compounds on the cultivated cells provide an indication of the antiobesity and antidiabetic effects of the compounds in humans.
US Patent 5,451,677 discloses selective B3 agonists of the formula:
Figure imgf000005_0001
PCT Application W095/29159 published November 2, 1995 (US Patent 5,561,142) discloses selective B3 agonists of the formula
Figure imgf000005_0002
Compounds of the present invention represent a novel selection within the disclosure of W095/29159.
SUMMARY OF THE INVENTION
The instant invention is concerned with oxadiazole substituted benzenesulfonamides which are useful as antiobesity and antidiabetic compounds. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the substituted sulfonamides. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.
DESCRIPTION OF THE INVENTION The present invention provides compounds having the formula I:
Figure imgf000006_0001
wherein
X is (1) a bond,
(2) C1-C3 alkylene optionally substituted with 1 or 2 groups selected from methyl, C 1 -C5 alkoxy, hydroxy, and halogen,
(3) C1-C3 alkylene optionally substituted with 1 or 2 groups selected from methyl, C | -C5 alkoxy, hydroxy, and halogen, wherein said alkylene contains up to two groups selected from Q and carbonyl,
(4) carbonyl, or
(5) Q; m is 0 to 5; A is (1) phenyl,
(2) a 5 or 6-membered heterocyclic ring with from
1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) a benzene ring fused to a C5-C10 carbocyclic ring,
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(5) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring; Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen, (c) cyano,
(d) QR2
(e) C3-C8 cycloalkyl,
(f) A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl- C 10 alkoxy,
(g) Q-COR3,
(h) S(0)nR3, where n is 0 to 2,
Figure imgf000007_0001
(2) C3-C8 cycloalkyl,
(3) oxo,
(4) halogen,
(5) cyano, (6) QR2,
(7) S(0)nR3, where n is 0 to 2„
(8) Q'COR3,
(9) NR2Sθ2R3,
(10) NR Cθ2R2, (11) A optionally substituted with up to 5 groups independently selected from
(a) R2,
(b) QR2,
(c) halogen, and (d) oxo; or
(12) CO2R2; R2 is (1) hydrogen,
(2) Cl-ClO alkyl optionally substituted with up to 5 groups selected from (a) hydroxy,
(b) halogen,
(c) CO2R4,
(d) S(O)n-Cl-C10 alkyl, where n is 0 to 2, (e) C3-C8 cycloalkyl,
(f) Cl-C 10 alkoxy, and
(g) A optionally substituted with up to 5 groups selected from halogen, C l-C 10 alkyl and Cl- ClO alkoxy, (3) C3-C8 cycloalkyl, or
(4) A optionally substituted with up to 5 groups selected from
(a) halogen,
(b) nitro, (c) oxo,
(d) NR4R4,
(e) Cl-C 10 alkoxy,
(f) S(O)n-Cl-Cl0 alkyl, where n is 0 to 2, and (g) C 1 -C 10 alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, CO2R4, S(O)n-Cl-Cl0 alkyl, where n is 0 to 2, C3-C8 cycloalkyl, Cl-C 10 alkoxy, and A optionally substituted with up to 5 groups selected from halogen, C 1 -C 10 alkyl and C 1 -
ClO alkoxy; R3 is (1) R2 or
(2) NR2R2; R4 is (1) H, or (2) Cl-ClO alkyl;
Q is (1) N(R2),
(2) O or
(3) S(0)n, and n is 0 to 2; Q' is (1) N(R2), (2) 0 or
(3) a bond; or a pharmaceutically acceptable salt thereof.
Compounds of the present invention are a novel selection within the generic structure disclosed in W095/29159.
The present compounds are potent and selective B3 agonists, and have improved oral bioavailability in animals.
In one subset of compounds of formula I X is C1-C3 alkylene, optionally substituted with one or two groups selected from methyl, and halogen. In one embodiment X is -CH2-,
CH(CH3)-, -C(CH3)2 or -CH(F)-, and a preferred embodiment is where X is -CH2-.
In another subset X is C1-C3 alkylene-O, C1-C3 alkylene-carbonyl or N(R2), wherein the alkylene is optionally substituted with one or two groups selected from methyl, and halogen. In one embodiment X is -CH2O- or -C(CH3)2θ-, wherein the point of attachment to the oxadiazole ring is the carbon atom and the point of attachment to the A group is the oxygen atom; and a preferred embodiment is where X is CH2O. The oxadiazole ring may be attached to the benzenesulfonamide moiety via either the C3 carbon or the C5 carbon atom. The numbering of the oxadiazole ring is as shown below:
Figure imgf000009_0001
Ia
Figure imgf000010_0001
lb
Another subset of compounds of formula I provides compounds wherein A is (1) phenyl, (2) naphthyl, (3) a 5 or 6- membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or (4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.
Another subset of compounds of formula I provides compounds where Rl is (l) Cl-Clθ alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, cyano, QR2, C3-C8 cycloalkyl, A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy, Q'COR3, S(0)nR3 where n is 0 to 2, NR2Sθ2R3, and NR2Cθ2R2, (2) halogen, (3) QR2, (4) S(0)nR3 where n is 0 to 2, (5) Q'COR3, (6) phenyl optionally substituted with up to 4 groups independently selected from R2, QR2 and halogen, or (7) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups independently selected from oxo, R2, QR2 and halogen.
In a preferred embodiment of compounds of formula I, X is CH2 or CH2O in which O is attached to A; A is (1) phenyl, (2) naphthyl, (3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or (4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; Rl is (1) Cl-ClO alkyl optionally substituted with up to 5 groups selected from halogen, cyano, QR2, and A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl- ClO alkoxy, (2) halogen, (3) phenyl optionally substituted with up to 5 groups independently selected from R2, QR2 and halogen, (4) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups independently selected from R2, QR2 and halogen, or (5) QR2; R2 is (1) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy, (2) A optionally substituted with up to 5 groups selected from halogen, NR4R4, Cl-ClO alkoxy, Cl-C 10 alkylthio, and Cl-C 10 alkyl optionally substituted with up to 5 groups selected from halogen, C3-C8 cycloalkyl, Cl-ClO alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy; Q is N(R2), O or S. In a more preferred embodiment, X is CH2 or CH2O in which O is attached to A; A is (1) phenyl, (2) naphthyl, (3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or (4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; R is (1) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from halogen, and A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy, (2) halogen, (3) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups selected from halogen, Cl-ClO alkyl and Cl-ClO alkoxy, or (4) QR2; R2 is Cl-ClO alkyl, optionally substituted with up to 5 halogen atoms; and Q is O.
Representative antiobesity and antidiabetic compounds of the present invention include the following: N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(5-methylisoxazol-3-yl)-[l,2,4]-oxadiazol-3- yljbenzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(4-fluorophenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, -[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-fluorophenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(2,5-difluorophenyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3,5-difluorophenyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N- [4- [2- [ [2-hydroxy-2-(3-ρyridinyl)ethy 1] amino] ethyl]ρheny l]-4- [5-(3-trifluoromethylphenyl)-[ 1 ,2,4]-oxadiazol-3- yljbenzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-nitrophenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyllphenyl]-4- [5- (3-methy lthiophenyl)- [ 1 ,2 ,4] -oxadiazol-3 - yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methylsulfonylphenyl)-[ 1 ,2,4]-oxadiazol-3- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(2-methylphenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methylphenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methoxyphenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-pyridyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(2,3-dimethoxyphenyl)-[ 1 ,2,4]-oxadiazol-3- yljbenzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-benzofuranyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(5-fluoro-2-indolyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[2-(4-fluorophenyl)ethyl]-[ 1 ,2,4]-oxadiazol-3- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyllamino]ethyl]phenyl]-4-
[5-[2-(3,4-difluorophenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4-
[5-[2-(4-methoxyphenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N- [4- [2- [[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[2-(phenyl)ethyl]-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[2-(4-chlorophenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[3-(phenyl)propyl]-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N- [4- [2- [ [2-hy droxy-2-(3-py ridinyl)ethy 1] amino]ethy 1] phenyl] -4-
[5-[3-(4-methoxyphenyl)propyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-fluorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4-
[5-(4-fluorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-chlorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4-difluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, -[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3,4,5-trifluorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4-
[5-[3,5-bis(trifluoromethyl)phenylmethyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4-
[5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-[l,2,4]-oxadiazol-
3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[[4-(trifluoromethyl)phenyl]methyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[[4-(methylthio)phenyl]methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4- [5-[[4-(methylsulfonyl)phenyl]methyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(biphen-4-ylmethyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[4-(2-pyridyl)phenylmethyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[4-(3-pyridyl)phenylmethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[(4-acetamido)phenylmethyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-chlorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N- [4- [2- [ [2-hydroxy-2-(3-pyridinyl)ethy 1] amino]ethy l]pheny 1] -4- [5-(2-bromophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-methylphenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,4-difluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,5-difluorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-pyridylmethyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-indolylmethyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-naphthylmethyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N- [4- [2- [ [2-hy droxy-2-(3-pyridinyl)ethy 1] amino] ethy l]pheny 1] -4-
[5-[(5-fluoro-3-indolyl)methyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-thienylmethyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[(5-chlorobenzo[b]thien-3-yl)methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, -[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[(benzo[b]thien-3-yl)methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[(2,3-dihydrobenzofuran-5-yl)methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-oxo-3-(4-fluorophenyl)propyl)-i 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4-
[5-(2-(naphthyloxy)methyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-fluorophenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4-difluorophenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-acetamidophenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-trifluoromethylphenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4-
[5-(4-tetrazol-5-ylphenoxymethyl)]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-acetyloxyphenoxymethyl)-i 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-methylphenoxymethyl)-[l,2,4]-oxadiazol-3- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-phenoxyethyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(phenylamino)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-fluorophenylamino)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N- [4- [2- [ [2-hy droxy-2- (3 -py ridiny l)ethy 1] amino] ethyl] phenyl] -4- [3-(3,4-difluorophenylmethyl)-[l,2,4]-oxadiazol-5- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[3-(4-fluorophenylmethyl)-[l,2,4]-oxadiazol-5- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4-methylenedioxyphenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-fluorophenylcarbonyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-chlorophenylcarbonyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [3-(4-fluorophenoxymethyl)-[ 1 ,2,4]-oxadiazol-5- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-trifluoromethoxyphenoxymethyl,)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-trifluoromethoxyphenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[l-(4-fluorophenyl)-l-methoxymethyl]-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -(3,4-difluorophenyl)- 1 -methoxymethyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -(4-fluorophenyl)- 1-ethoxymethyl]- [ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5- [ 1 -(4-chlorophenyl)- 1 -methoxymethyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, and
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[ l-(4-chlorophenyl)-l-ethoxymethyl]-[ 1 ,2,4]-oxadiazol-3- yl] benzenesulfonamide, N-f4-r2-r[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- r5-(2-naphthyl)-ri,2,4]-oxadiazol-3-yl]benzenesulfonamide,.
N-f4-[2-ff2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(6-quinolinyl)-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide,.
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methoxyphenoxymethyl)-[ l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-f[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-chlorophenoxymethyl)-[ l,2,41-oxadiazol-3- yl]benzenesulfonamide, N-[4-r2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyn-4- 5-(4-isopropylphenoxymethyl)-fl ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-ff2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-chlorophenoxymethyl)-r 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-[2-f[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- f 5-(3,4-dichlorophenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-f2-ff2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyll-4- [5-(4-tert-butylρhenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-fr2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-sulfonamidophenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N_f4-[2-[f2-hydroxy-2-(3-pyridiny])ethyl]amino]ethyl]phenyl]-4-
[5-(3-chloronaphthyl- 1 -yloxymethyl)- f 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(5-indanyloxymethyl)-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N- r4- [2- [ [2-hydroxy-2- (3 -pyridiny l)ethy 1] amino]ethy 1] pheny 1] -4-
[5-(4-indanyloxymethyl)-[l,2,4]-oxadiazol-3- y 1] benzenesulf onamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-chlorophenoxymethyl)-[l,2,4]-oxadiazol-3- yl ] benzenesulfonamide,
N-[4-[2-[f2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,5-dichlorophenoxymethyl)-fl,2,4]-oxadiazol-3- yl] benzenesulfonamide,
N-f4-[2-[f2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-trifluoromethoxyphenoxymethyl)-fl,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-r4-[2-[r2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- r5-r4-(l,2-benzisoxazol-3-yl)-2,3-dichlorophenoxymethyl]-f 1,2,4]- oxadiazol-3-yl]benzenesulfonamide,
N-[4-[2-ff2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,4-dichlorophenoxymethyl)-f 1 ,2,4]-oxadiazol-3- yl] benzenesulfonamide, N-[4-r2-[r2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5- [4- (2-quinazoliny l)phenoxy methyl ] - f 1 ,2 ,4] -oxadiazol-3- yl] benzenesulfonamide,
N-f4-[2-[r2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,4,5-trichlorophenoxymethyl)-f 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-r4-r2-[r2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,3-dichlorophenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-f4-[2-f[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-chloro-4-tert-butylphenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-f2-rf2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5- 2,3-dichloro-4-(2-thienylsulfonyl)phenoxymethyl]-f 1 ,2,4]- oxadiazol-3-yl]benzenesulfonamide,
N-f4-[2-ff2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-f4-(N,N-dipropylsulfamoyl)phenoxymethyl]-[l,2,4]-oxadiazol-
3-yl]benzenesulfonamide, N-[4-r2-[f2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- f5-(4-trifluoromethylphenyl)- l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4- 2-[f2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- r5-(4-trifluoromethoxyphenyl)-fl,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-f2-rr2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4,5-trifluorophenyl)-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-r4-r2-f[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(6-fluoronaphth-2-yloxymethyl,)-[l ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-r4-[2-f[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(6-fluoronaphth-2-ylmethyl,)-fl,2,4]-oxadiazol-3- y 1 ] benzenesulfonamide, N-[4-[2-rf2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-f l-fluoro-l-(4-trifluoromethylphenyl)methyl]-[l,2,4]-oxadiazol-
3-yl]benzenesulfonamide,
N-f4-[2-rf2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4- f 5-f 1 -(4-trifluorornethylρhenyl)- 1 -ethyl]-f 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N_f4-f2-ff2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]ρhenyl]-4-
[5-f]-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide,
N-f4-r2-ff2-hydroxy-2-(pyridin-3-yl)ethyllamino]ethyl]ρhenyl]-4-
[5-π-fl,2,4]-oxadiazol-3-yl]benzenesulfonamide, N-f4-[2-ff2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-f]-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-f]-fl,2,4]-oxadiazol-3-yl]benzenesulfonamide, N-[4- 2-fr2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4-
[5-[l-(4-ιluorophenoxy)-l-methylethyl]-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-[2-[r2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -( 1 -naphthyloxy)- 1-methylethyl]- [ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-[2-f[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-f l-(2-naphthyloxy)-l-methylethyl]-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-F2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- r5-f l-(4-chlorophenoxy)-l-methylethyl]-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-[2-[r2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-f l-(2-chlorophenoxy)-l-methylethyl]-fl,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-f4-r2-r[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- r5-r 1 , 1 -difluoro- 1 -(phenyl)methyl]-[ 1 ,2,4]-oxadiazol-3- yllbenzenesulfonamide,
N-[4-f2-r[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -(4-(4-chlorophenyl)ρhenoxy )- 1 -methylethyl]-[ 1 ,2,4]- oxadiazol-3-yl]benzenesulfonamide,
N-[4-f2-[f2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -(4-chlorophenyl)- 1 -methylethyl]- [ 1 ,2,4]-oxadiazol-3- y 1] benzenesulfonamide ,
N-f4-r2-rf2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]ρhenyll-4- [5- [ 1 -(4-trifluoromethoxy phenyl)- 1 -ethyI]-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-f2-rf2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -fluoro- 1 -(4-trifluoromethoxyphenyl)methyl]-r 1 ,2,4]- oxadiazol-3-yl]benzenesulfonamide, N-f4-f2-[f2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-ri-(6-fluoronaphth-2-yl)-l-hydroxymethyl]-ri,2,4]-oxadiazol-3- y 1 ] benzenesulfonamide ,
N- [4- [2- [ [2-hy droxy-2- (pyridin-3 -y l)ethy 1] amino] ethyl]pheny l]-4- [5-fl-(6-fluoronaphth-2-yl)-l-ethyll-ri,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[r2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[l-(6-fluoronaphth-2-yl)-l-methylethyl]-ri,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-f4-r2-rf2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]ρhenyll-4- [3-(4-trifluoromethylphenyl)-[ 1 ,2,4]-oxadiazol-5- yl]benzenesulfonamide,
M-[4-[2-[r2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [3-(4-trifluoromethoxyphenyl)-[l,2,4]-oxadiazol-5- yl]benzenesulfonamide.
The compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in structural Formula I. Additional asymmetric centers may be present on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof, be included within the ambit of the instant invention. In the case of the asymmetric center represented by the asterisk in Formula I, it has been found that the compound in which the hydroxy substituent is above the plane of the structure, as seen in Formula Ic, is more active and thus more preferred over the compound in which the hydroxy substituent is below the plane of the structure.
The following stereospecific structure represents the preferred stereoisomers of the instant invention:
Figure imgf000023_0001
Ic
Throughout the instant application, the following terms have the indicated meanings:
"Alkylene" means -(CH2)p- where p is the designated carbon number. Optionally substituted alkylene may have one or two of the hydrogen atoms replaced with the same or different enumerated substituents. Where the alkylene contains up to two groups selected from Q, and carbonyl, the Q, or carbonyl group may be at either end of the alkylene chain, or it may be embedded within the chain. Examples include OCH(CH3), OC(CH3)2, C(CH3)2θ, OCH2, CH20, C(0)CH2, CH2OCH2, OC(0)CH2, OCH2CH2C(0), OCH2CH2O, OCH2CH2C(0)CH2, CH2CH(OCH3)CH2, CH(OCH3)CH2, etc.
The alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration. Exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
The alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like. The term "halogen" is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
The term "carbocyclic ring" is intended to include both aromatic and nonaromatic rings containing only carbon atoms. Thus, a benzene ring fused to a C5-C10 carbocyclic ring, includes naphthyl, tetrahydronaphthyl, indanyl and indenyl. A 5 or 6- membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5 -ClO carbocyclic ring includes benzene fused to a heterocyclic ring as well as a non- aromatic carbocyclic ring fused to a heterocyclic ring. The carbocyclic ring preferably is C5-C7.
A 5 and 6-membered heterocyclic ring, whether isolated or as a part of a fused ring system, is intended to include aromatic and unsaturated non-aromatic heterocycles; and where the heterocycle is part of a fused ring, at least one of the rings is aromatic. Examples of a 5 or 6-membered ring include pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, oxazolyl, imidazolidinyl, pyrazolyl, isoxazolyl. Examples of a benzene ring fused to a 5 or 6-membered heterocyclic ring include benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, 2,3-dihydrobenzofuranyl, quinolinyl, benzotriazolyl, benzoxazolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl. Examples of a 5 or 6-membered heterocyclic ring fused to a 5 or 6-membered heterocyclic ring incude purinyl, furopyridine and thienopyridine. Examples of a 5 or 6-membered heterocyclic ring fused to a non-aromatic carbocyclic ring include tetrahydrobenzothiazolyl, 5,6,7,8- tetrahydroquinolinyl, 2,3-cyclopentenopyridyl, 4,5,6,7- tetrahydroindolyl, 5,6,7, 8-tetrahydroisoquinolyl, 5,6,7,8- tetrahy droquinoxaliny 1.
The preferred values of A are phenyl, naphthyl, benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or heterocycles with from 1 to 4 heteroatoms independently selected from one of oxygen or sulfur, and/or 1 to 4 nitrogen atoms. The more preferred values of A are phenyl, naphthyl, thienyl, pyridinyl, pyrrolyl, benzothienyl, and 2,3- dihydrobenzofuranyl.
Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other; thus for example, NR2R2 may represent NH2, NHCH3, N(CH3)CH2CH3, and the like.
The following abbreviations are used throughout the specification:
AcOH : acetic acid AR : adrenergic receptor
Boc BOC : tert-butyloxycarbonyl
CHO : Chinese hamster ovary
DBU : l,8-diazabicyclo[5.4.0]undec-7-ene
DCC : dicyclohexycarbodiimide DCM : dichloromethane
DIEA : diisopropylethylamine
DMF : dimethylformamide
EDC : l-(3-dimethylaminopropyl)-3- ethylcarbodiimide EtOAc : ethyl acetate
HPLC : high pressure liquid chromatography iPrOH : isopropyl alcohol
NMR : nuclear magnetic resonance
TES : triethylsilyl TFA : trifluoroacetic acid
THF : tetrahydrofuran
TLC : thin layer chromatography
The compounds (I) of the present invention can be prepared as described in the following schemes. For oxadiazoles Ia where X is other than Q or Q-CI-C3 alkylene, as illustrated in Scheme 1, the protected aniline derivative 1 (See Fisher, et. al., W09529159-A, Nov. 2, 1995, for the synthesis of this compound.) is treated with a 4-cyanobenzenesulfonyl halide, conveniently the sulfonyl chloride 2, and a base such as pyridine in an anhydrous solvent such as dichloromethane or chloroform for 0.5 to 24 hours at temperatures of -20 to 50°C, preferably 0°C, to provide the sulfonamide 2. Treatment of sulfonamide 2 with hydroxylamine, which may be formed in situ from hydroxylamine hydrochloride and a base such as potassium carbonate, in a solvent such as ethanol at temperatures from 0 °C to 100 °C, conveniently 70-80 °C, provides the corresponding amidoxime 4. The oxadiazole is then formed by methods known in the literature (See, for example, Borg, et. al., J. Org. Chem. 1995, 60, 3112-3120 and Diana, et. aL, J. Med. Chem. 1994, 37, 2421-2436, and references cited therein). This is conveniently carried out by acylation with an acid halide such as the acid chloride £ (X = Cl) or an anhydride 5 (X = OCOR) including mixed anhydrides in the presence of base or with an acid 5 (X = OH) and a peptide coupling reagent such as ethyldimethylaminopropylcarbodiimide, followed by heating to effect cyclization in a solvent such as pyridine or diglyme. Removal of the protecting group with, in the case of a tert- butylcarbamate, acid such as trifluoroacetic acid or methanolic hydrogen chloride, provides the oxadiazole Ia. The carboxylic acids or acid derivatives 5 are commercially available, known in the literature, or readily prepared by methods commonly known to those skilled in the art.
In some cases, the product Ia from the reaction described in Scheme 1 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on Rl . These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. SCHEME 1.
Figure imgf000027_0001
Figure imgf000027_0002
The method employed in Scheme 1 relies on masking the secondary amine in the final product as an N-Boc derivative. Alternate protecting groups for this secondary amine, which are readily known to those skilled in the art, may be employed. In addition, the reactions illustrated in Scheme 1 may be carried out on a solid phase support linkage. This approach is illustrated in Schemes 2 and 3. As shown in Scheme 2, aniline derivative 6 is coupled to a solid support such as NovaSyn® TGA resin from Novabiochem (7) by treatment with an activating agent, conveniently 4-nitrophenyl chloroformate in the presence of base such as diisopropylethylamine in a solvent or solvent mixture such as 1:1 tetrahydrofuran / dichloromethane. The hydroxyl group is then protected, conveniently as its triethylsilyl ether using triethylsilyl chloride in the presence Of a base such as diisopropylethylamine. The resultant derivative 8 is treated with 4- cyanobenzenesulfonyl halide, conveniently the sulfonyl chloride 2, in the presence of a base such as pyridine, to provide the sulfonamide 2. Treatment of intermediate 2 with hydroxylamine as described above provides the corresponding amidoxime IQ.
SCHEME 2.
r)
Figure imgf000030_0001
The oxadiazoles Ia are prepared from intermediate JO as illustrated in Scheme 3. Treatment of the resin-bound amidoxime with an acid, acid chloride or anhydride 5 as described above, in a solvent such as diglyme with heating, conveniently to 90-110 °C, gives the resin-bound oxadiazole. Cleavage from the resin is effected, in the case of Novasyn TGA resin from Novabiochem, by treatment with acid such as trifluoroacetic acid as a 1 :1 mixture with dichloromethane.
SCHEME 3.
Figure imgf000031_0001
5, X = OH, Cl, OCOR
10 ►
2) heat
3) TFA/CH2CI2
Figure imgf000031_0002
For cases where X = NH in Formula Ia, the oxadiazole may be prepared from the corresponding isocyanidedichloride (See for example, Japan Patent 05117255, 1993). As shown in Scheme 4, intermediate 4 is treated with isocyanidedichloride ϋ and a base such as DBU. Removal of the Boc protecting group under acidic conditions, for example, with trifluoroacetic acid in dichloromethane, provides the desired oxadiazoles Ia. The requisite isocyanidedichlorides JT are known in the literature (for example, Kuhle, Angew. Chem. 1962, 74, 861-866) or readily prepared by methods known to those skilled in the art.
SCHEME 4.
Figure imgf000032_0001
For cases where X contains a sulfur or oxygen directly attached to the oxadiazole ring, compounds Ia may be prepared by reaction of the corresponding thiol or alcohol with an activated oxadiazole. As shown in Scheme 5, the amidoxime 4 is treated with trichloroacetyl chloride in a base such as pyridine followed by heating to provide the corresponding oxadiazole 12. Displacement of the trichloromethyl group with an alcohol or thiol 13 in the presence of a base and subsequent deprotection of the Boc secondary amine with acid such as trifluoroacetic acid gives the desired oxadiazoles Ia. SCHEME 5.
Figure imgf000033_0001
(X = S(CH2)n or O(CH2)n, n = 0-3)
Figure imgf000033_0002
In some cases, the product Ia from the reactions described in Schemes 4 and 5 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on Rl . These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. The isomeric oxadiazoles lb are readily available as illustrated in Scheme 6. Aniline derivative 1 is sulfonylated by treatment with 4-(chlorosulfonyl)benzoic acid (14) in the presence of a base such as pyridine to provide the corresponding sulfonamide 15_. The oxadiazole is then formed as described above by treatment of 15 with the appropriate amidoxime J_6 in the presence of a peptide coupling reagent such as dicyclohexylcarbodiimide or N-ethyl-N'- dimethylaminopropylcarbodiimide, followed by heating to effect cyclization in a solvent such as pyridine or diglyme. Removal of the protecting group with, in the case of a tert-butylcarbamate, acid such as trifluoroacetic acid or methariolic hydrogen chloride, provides the oxadiazole lb. The amidoximes 16 are commercially available, known in the literature, or readily prepared by methods commonly known to those skilled in the art. Conveniently, they are prepared from the corresponding nitrile by treatment with hydroxylamine.
In some cases, the product lb from the reaction described in Scheme 6 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on Rl . These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.
SCHEME 6.
Figure imgf000035_0001
2) heat
3) TFA/CH2CI2
Figure imgf000035_0002
An alternate approach to compounds lb which involves the coupling of an oxadiazolylbenzenesulfonyl chloride to the aniline intermediate 1 is shown in Scheme 7. Amidoxime 16 is coupled to a protected 4-aminobenzoic acid derivative such as Boc- protected amine 17 using a coupling reagent such as EDC or DCC, followed by heating to effect ring closure. The resultant oxadiazole 18 is treated, in the case of a N-Boc-protected derivative, with trifluoroacetic acid. The resultant aniline is diazatized with, for example, sodium nitrite and then treated with sulfur dioxide and copper(I) chloride to provide the corresponding sulfonyl chloride 19. Coupling of sulfonyl chloride 19 and aniline intermediate 1 in the presence of base such as pyridine followed by deprotection with trifluoroacetic acid gives the desired oxadiazoles lb.
SCHEME 7.
Figure imgf000036_0001
2) heat
Figure imgf000036_0002
Compounds of the general Formula I may be present as pairs of enantiomers or, where there is more than one chiral centers, as mixtures of diastereomers. Enantiomeric pairs may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent. A mixture of diastereomers may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers may be separated as described above
Alternatively, any enantiomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials of known configuration.
The instant compounds can be isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic and the like. In addition, certain compounds containing an acidic function such as a carboxy or tetrazole, can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
As previously indicated, the compounds of the present invention have valuable pharmacological properties. Thus the present invention also provides a compound of the general Formula I or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance.
The disease diabetes mellitus is characterized by metabolic defects in production and utilization of glucose which result in the failure to maintain appropriate blood sugar levels. The result of these defects is elevated blood glucose or hyperglycemia. Research on the treatment of diabetes has centered on attempts to normalize fasting and postprandial blood glucose levels. Treatments have included parenteral administration of exogenous insulin, oral administration of drugs and dietary therapies. Two major forms of diabetes mellitus are now recognized. Type I diabetes, or insulin-dependent diabetes, is the result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type II diabetes, or insulin- independent diabetes, often occurs in the face of normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin. Most of the Type II diabetics are also obese.
Compounds of the present invention are capable of stimulating β3 adrenoceptor mediated lipolysis, and lowering blood glucose levels. Thus, in one aspect, the present invention provides a compound of the general Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of obesity or hyperglycemia (diabetes) in human or non-human animals. In another aspect, the present invention provides a method for the treatment of obesity which comprises administering to an obese patient a therapeutically effective amount of a compound of the general Formula I, or a pharmaceutically acceptable salt thereof. In a further aspect, the present invention provides a method for the treatment of diabetes which comprises administering to a diabetic patient a therapeutically effective amount of a compound of formula I.
In addition the compounds of the present invention lower triglyceride levels and cholesterol levels and raise high density lipoprotein levels and are therefore of use in combatting medical conditions wherein such lowering (and raising) is thought to be beneficial. Thus they may be used in the treatment of hyper- triglyceridaemia, hypercholesterolaemia and conditions of low HDL (high density lipoprotein) levels in addition to the treatment of atherosclerotic disease such as of coronary, cerebrovascular and peripheral arteries, cardiovascular disease and related conditions. Accordingly, in another aspect the present invention provides a method of lowering triglyceride and/or cholesterol levels and/or increasing high density lipoprotein levels which comprises administering, to a human or a non-human animal in need thereof, a therapeutically effective amount of a compound of the formula (I) or pharmaceutically acceptable salt thereof. In a further aspect the present invention provides a method of treating atherosclerosis which comprises administering, to an animal in need thereof; a therapeutically effective amount of a compound of the formula (I) or pharmaceutically acceptable salt thereof. The compositions are formulated and administered in the same general manner as detailed below for treating diabetes and obesity. They may also contain other active ingredients known for use in the treatment of atherosclerosis and related conditions, for example fibrates such as clofibrate, bezafibrate and gemfibrozil; inhibitors of cholesterol biosynthesis such as HMG-CoA reductase inhibitors for example lovastatin, simvastatin and pravastatin; inhibitors of cholesterol absoφtion for example beta-sitosterol and (acyl Co A: cholesterol acyltransferase) inhibitors for example melinamide; anion exchange resins for example cholestyramine, colestipol or a dialkylaminoalkyl derivatives of a cross-linked dextran; nicotinyl alcohol, nicotinic acid or a salt thereof; vitamin E; and thyromimetics.
The compounds of the instant invention also have the effect of reducing intestinal motility and thus find utility as aiding in the treatment of various gastrointestinal disorders such as irritable bowel syndrome. It has been proposed that the motility of non-sphincteric smooth muscle contraction is mediated by activity at β3 adrenoreceptors. The availability of a β3 specific agonist, with little activity at βl and β2 receptors will assist in the pharmacologic control of intestinal motility without concurrent cardiovascular effects. The instant compounds are administered generally as described below with dosages similar to those used for the treatment of diabetes and obesity.
It has also been found unexpectedly that the compounds which act as agonists at β3 adrenoreceptors may be useful in the treatment of gastrointestinal disorders, especially peptic ulcerations, esophagitis, gastritis and duodenitis, (including that induced by H. pylori), intestinal ulcerations (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis) and gastrointestinal ulcerations. In addition, β3 receptors have been indicated to have an effect on the inhibition of the release of neuropeptides in certain sensory fibers in the lung. As sensory nerves may play an important role in the neurogenic inflammation of airways, including cough, the instant specific β3 agonists may be useful in the treatment of neurogenetic inflammation , such as asthma, with minimal effects on the cardio-pulmonary system. β3 adrenoreceptors are also able to produce selective antidepressant effects by stimulating the β3 receptors in the brain and thus an additional contemplated utility of the compounds of this invention are as antidepressant agents.
The active compounds of the present invention may be orally administered as a pharmaceutical composition, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or they may be incoφorated directly with the food of the diet. For oral therapeutic administration, which includes sublingual administration, these active compounds may be incoφorated with excipients and used in the form of tablets, pills, capsules, ampules, sachets, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated.
When treating diabetes mellitus and/or hyperglycemia generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.07 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
When treating obesity, in conjunction with diabetes and/or hyperglycemia, or alone, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from 0.01 milligram to about 100 milligrams per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.7 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
These active compounds may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
The following in vitro assays are suitable for screening compounds that have selective β3 agonist activity:
Functional Assay: cAMP production in response to ligand is measured according to Barton et al (1991, Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Mol. Pharmacol. v3229:650-658) modified as follows. CHO cells, stably transfected with the cloned β-adrenergic receptor (βl , β2 or ββ) are harvested after 3 days of subculturing. Harvesting is done with Enzyme-free Dissociation Media (Specialty Media). Cells are counted and distributed in the assay tubes, after being resuspended in Tris buffer (ACC buffer: 75 mM Tris, pH 7.4, 250 mM Sucrose, 12.5 mM MgCl2, 1.5 mM EDTA, 0.2 mM Sodium Metabisulfite, 0.6mM IBMX) containing an antioxidant and a phosphodiesterase inhibitor. Reaction is initiated by mixing 200,000 cells in 100 μL with 20 μL of a 6x stock of ligand/unknown to be tested. Tubes shake at 275 φra for 45 min at room temperature. The reaction is stopped by boiling the tubes for 3 min. The cell lysate is diluted 5-fold in 0.1 N HCI and then acetylated by the mixture of 150 μL of acid-diluted sample with 6 μL of acetylation mixture (acetic anhydride/triethylamine, 1 :2.5). The cAMP produced in response to the ligand is measured in the lysate by competing against 25l-cAMP for binding to a 25ι_cAMP-directed antibody using an automated RIA machine (ATTOFLO, Atto Instruments, Baltimore, MD, Brooker et al 1979, Radioimmunoassay of Cyclic AMP and Cyclic GMP. Advances in Cyclic Nucleotide Research, vol 10: 1-32.). The unknown cAMP level is determined by comparing levels to a standard curve. Alternatively, cAMP is measured using the cAMP SPA kit (code number RPA 556) from Amersham according to the manufacturer's instructions. Samples tested with the latter method do not need to be acetylated.
The non-selective, full agonist β-adrenergic ligand isoproterenol is used at all three receptors to determine maximal stimulation. The human β3 AR-selective ligand (S)-N-[4-[2-[[2- hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-4- iodobenzenesulfonamide is used as a control in all assays. Isoproterenol is titrated at a final concentration in the assay of 10" 10 M to 10~5 M for the β3 AR and 10"1 M to 10"6 M for the βl AR and β2 AR assays. L- 742,791 is titrated at the β3 receptor at concentration of 10"! 1 M to 10"6 M. At the βl AR the concentrations used are 10"8 M, 10"7 M, 3X10"7 M, 10-6 M, 3X10"6 M and 10"5 M. For the B2 AR a single concentration of 10"5 M is used.
Unknown ligands are initially tested at the β3 AR at a final concentration in the assay of 10~7 M. Compounds that have an activation at this concentration equal to or greater than 35% of the isoproterenol stimulation are titrated at the β3 AR at concentrations equal to those used to titrate the control (S)-N-[4-[2-[[2-hydroxy-3-(4- hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-4- iodobenzenesulfonamide to determine the EC50. The EC50 is defined as the concentration of compound that gives 50% activation of its own maximum. Data are analyzed using the Prism program (GraphPan, San Diego, CA).
A selective compound is defined as a compound with a (EC50 β3 AR)/(IC50 βl AR, β2 AR) greater than 100. IC50 is defined in the next section. Selective compounds are tested for agonist activity at the βl AR and the β2 AR by assaying first at a single concentration, 10"5 M. Compounds with activations of less than 20% when compared to the isoproterenol control (βl AR and β2 AR) are retested at 10"7 M and 10"5 M. Compounds with activations between 20% and 40% and other compounds of interest are titrated at the following concentrations: 10-8 M, lO"7 M, 10-6 M, 3X10"6 M, 10"5 M and 3X10-5 M. Compounds with activities greater than 40% are not tested further.
Binding Assay: Compounds are also assayed at the βl and B2 receptors to determine selectivity. This is done for all compounds using a 6 point binding assay as follows: CHO cells expressing the βl and the β2 receptors are grown for 3-4 days after splitting. The attached cells are washed with PBS and lysed in ImM Tris, pH 7.2 for 10 minutes in ice. The flasks are scraped and the membranes centrifuged at 38,000 x g for 15 minutes at 4 °C. The membranes are resuspended in TME buffer (75 mM Tris, pH 7.4, 12.5 mM MgCl2, 1.5 mM EDTA) at a concentration of 1 mg protein/ml. Large batches of membranes can be prepared, aliquoted and stored at -70°C for up to a year without loss of potency. The binding assay is performed by incubating together membranes (20-50 μg of protein), the radiolabelled tracer 125 j_ cyanopindolol ( 25i_CYP, 45pM), and the test compounds at final concentrations ranging from 10" 0 M to 10-5 M in a final volume of 250 μL of TME buffer. The tubes are incubated for 1 hour with shaking at room temperature and the samples are filtered in an IMSCO 96-well cell harvester. The filters are counted in a Gamma counter and the data are analyzed using a 4 parameter fit routine in RS 1 (program developed in house using well documented statistical analysis programs) to determine the IC50. The IC50 is defined as the concentration of the compound capable of inhibiting 50% of the binding of the radiolabelled tracer (125j_cγp) Compounds having >100 fold selectivity are also tested for agonist activity at the βl and β2 receptors following the protocols already described for the B3 AR above.
The following examples are provided so that the invention might be more fully understood. They should not be construed as limiting the invention in any way.
EXAMPLE 1
Figure imgf000045_0001
(R)-N-f4- \2- rN-( 1.1 -DimethylethoxycarbonylVN- r2-hydroxy-2- (pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- cyanobenzenesulfonamide
To a solution of 2.18 mmol of (R)-N-[2-[4-(aminophenyl)]ethyl]-2- hydroxy-2-(pyrid-3-yl)ethylcarbamic acid 1,1-dimethylethyl ester (See Fisher, et. al., W09529159-A, Nov. 2, 1995, for the synthesis of this compound.) in 10 mL of methylene chloride at room temperature was added 160 uL of pyridine followed by 450 mg of 4-cyanobenzenesulfonyl chloride. The resultant mixture was stirred overnight. TLC (acetone 25%, methylene chloride 75%) on silica indicated the formation of a major fast moving (rf 0.48) spot. Purification by flash chromatography gave 716 mg of the title compound as a white solid: iH NMR (400 MHz, CDCI3) d 8.53- 8.44(m, 2H), 7.78 and 8.67 each (d, J=8.7 Hz, 2H), 7.3(m, IH), 7.1-6.9(m, 4H), 4.8(m, IH), 3.5-2.6(m, 6H), 1.42(s, 9H).
EXAMPLE 2
Figure imgf000046_0001
(R)-N-r4-r2-rN-(l.l-Dimethylethoxycarbonvn-N-r2-hvdroxy-2- ψyridin-3-yltethyl1amino1ethyllphenyl]-4- (aminooximidomethyl)benzenesulfonamide Fifteen g of finely ground K2CO3 was suspended in 150 mL of absolute ethanol and after about 1 hr. 9 g of the nitrile from Example 1 and 6 g of hydroxylamine hydrochloride were added and stirred under reflux for 16 hr. The reaction mixture was cooled to room temperature and treated with 150 mL of methylene chloride and filtered through a bed of silica (30g). The silica was washed with 200 mL of 20% methanol/methylene chloride, and the combined filtrate evaporated and dried under vacuum overnight to yield 9 g of the title compound as a white solid: H NMR (400 MHz, CD3OD) δ 8.50-8.40(m, 2H), 7.93-7.67(m, 5H), 7.40(m, IH), 7.08-6.96(m, 4H), 4.84(m, IH), 3.4-2.6(m, 6H), 1.32 (s, 9H).
EXAMPLE 3
Figure imgf000047_0001
(R -N-r4-r2-rr2-Hvdroxy-2-(pyridin-3- vπethyllamino1ethvnphenyl]-4-r5-(4-fluorophenylmethylVπ.2.41- oxadiazol-3-ynbenzenesuIfonamide A suspension of 550 mg of the amidoxime from Example 2, 210 mg of EDC, and 160 mg of 4-fluorophenylacetic acid in 7 mL of diglyme was heated (oil bath temp. 110 degrees) while stirring. TLC analysis after 1 h indicated the formation of a new spot more mobile than the amidoxime (rf 0.61, methanol/methylene chloride 7/93). Following overnight heating, this converted to a new more mobile spot (rf 0.72). Purification by flash chromatography on slica and deprotection of the BOC group by treatment with 1: 1 TFA methylene chloride, neutralization with 10% ammonium hydroxide in methanol, and purification by flash chromatography (silica, aqueous ammonium hydroxide, methanol, dichloromethane 1/9/90) gave 305 mg of the title compound: iH NMR (400 MHz, CD3OD) δ 8.51(d, J=2.26Hz, IH), 8.42-8.40(m, IH), 8.1 l(d, J=8.6Hz, 2H), 7.82(d, J=8.6Hz, 2H), 7.79(m, IH), 7.4-7.37(m, 3H), 7.08 & 7.01(ea. d, J=8.5Hz, ea. 2H), 7.01(m, 2H), 4.78(m, IH), 4.33(s, 2H), 2.9-2.7(m, 6H).
EXAMPLE 4
Figure imgf000048_0001
(R)-N-[4-r2-rr2-Hvdroxy-2-(pyridin-3- yl)ethyllamino1ethyl1phenyl]-4-r5-(4-chlorophenylmethyl)-π.2.41- oxadiazol-3-yl]benzenesulfonamide
The title compound was prepared as described above for Example 3: iH NMR (400 MHz, CD3OD) δ 8.51(d, J=1.6Hz, IH), 8.42- 8.40(m, IH), 8.1 l(d, J=8.34Hz, 2H), 7.82(d, J=8.34Hz, 2H), 7.79(m, IH), 7.4-7.3(m, 5H), 7.08 & 7.01(ea. d, J=8.35Hz, ea. 2H), 4.78(m, IH), 4.33(s, 2H), 2.9-2.7(m, 6H).
EXAMPLE 5
Figure imgf000048_0002
(R)-N-r4-r2-rr2-Hvdroxy-2-(pyridin-3- yl)ethyllaminolethvnphenyIl-4-r5-G.4-difluorophenylmethylV f 1.2.4]-oxadiazol-3-yl1benzenesulfonamide The title compound was prepared as described above for Example 3: iH NMR (400 MHz, CD3OD) δ 8.52(d, J=2.2Hz, IH), 8.42- 8.40(m, IH), 8.12(d, J=8.58Hz, 2H), 7.83(d, J=8.58Hz, 2H), 7.8(m, IH), 7.4-7.14(m, 4H), 7.09 & 7.02(ea. d, J=8.5Hz, ea. 2H), 4.78(m, IH), 4.35(s, 2H), 2.9-2.7(m, 6H).
EXAMPLE 6
(R)-N-,4-r2-rr2-Hvdroxy-2-ψyridin-3- vDethyl1aminolethyl1phenyl1-4-r5-G.4-difluorophenylmethylV π.2.41-oxadiazol-3-yl]benzenesulfonamide dihydrochloride salt The free base prepared above in Example 5 (500 mg) was dissolved in 1.5 mL of methanol and treated with a solution that contains 210 uL of acetyl chloride in methanol and stirred at 0 °C for 30 min. Solvent was evaporated and the residue dried under vacuum overnight to give the dihydrochloride salt as a white solid: iH NMR (400 MHz, CD3OD) δ 8.97(d, J=1.2Hz, IH), 8.86(d, J=5.81, 1H), 8.70(d, J=8.07, IH), 8.12(d, J=8.53Hz, 2H), 8!(m, IH), 7.87(d, J=8.53Hz, 2H), 7.4-7.2(m, 4H), 7.17 & 7!0(ea. d, J=8.58Hz, ea. 2H), 5.3(m, IH), 4.37(s, 2H), 2.9-3.5(m, 6H).
EXAMPLE 7
Figure imgf000049_0001
(RVN-F4-r2-rr2-Hvdroxy-2-(pyridin- 2yl)ethyllaminolethyllphenyll-4-r5-r(thiophen-3-yl1methyll- π.2.41-oxadiazol-3-yl1benzenesulfonamide The title compound was prepared as described above for Example 3: !H NMR (400 MHz, CD3OD, ppm) δ 2.70-2.90 (m, 6H), 4.37 (s, 2H), 4.83 (m, IH), 7.0-7.1 (m, 5H), 7.3-7.4 (m, 3H), 7.82 (m, 3H), 8.13 (m, 2H), 8.42 (m, IH), 8.51 (m, IH).
EXAMPLE 8
Figure imgf000050_0001
(R -N-r4-f2-rr2-Hvdroxy-2-tpyridin-3- v ethyl1amino]ethyllphenyll-4-r5-r2-(4-fluorophenyl)ethvn- f 1.2.4]-oxadiazol-3-yllbenzenesulfonamide
The title compound was prepared as described above for Example
3: Selected iH NMR Data (400 MHz, CD3OD) δ 8.12(d,
J=8.30Hz, 2H), 7.83(d, J=8.48Hz, 2H), 7.24(m, 2H), 6.97(m, 2H),
3.27(t, J=7.06Hz, 2H), 3.15(t, J=7.24Hz, 2H).
EXAMPLE 9
Figure imgf000050_0002
(R -N-r4-r2-rr2-Hvdroxy-2-(pyridin-3- yl)ethyl]aπύnolethyllphenyl]-4-r5-G-phenyl)propyl]-r 1.2.41- oxadiazol-3-yl]benzenesulfonamide
The title compound was prepared as described above for Example
3: Selected iH NMR Data (400 MHz, CD3OD) δ 8.10(d,
J=8.62Hz, 2H), 7.83(d, J=8.57Hz, 2H), 7.24(m, 1H), 7!6(m, 4H),
2.94(t, J=7.52Hz, 2H), 2.82(m, 2H), 2.14(qn, J=7.42Hz, 2H).
EXAMPLE 10
Figure imgf000051_0001
Step A: Preparation of the Resin-Bound Aniline. To 10 g of NovaSyn® TGA resin from Novabiochem in 30 mL of 1 : 1 tetrahydrofuran/dichloromethane (THF/DCM) was added 4 mL of diisopropylethylamine (DIEA) and 5 g of 4-nitrophenyl chloroformate. The resultant mixture was stirred overnight. The resin was thoroughly washed with THF/DCM until the eluate was colorless, treated with 2 mL of DIEA and 2 g of (R)-N-[2-[4- (aminophenyl)]ethyl]-2-hydroxy-2-(pyrid-3-yl)ethylamine (See Fisher, et. al., W09529159-A, Nov. 2, 1995, for the synthesis of this compound.) in 20 mL of DMF, and allowed to stir overnight. The resin was washed with DMF, treated with 2 mL of DIEA, 2 mL of triethylsilyl chloride and 10 mL of DMF, and allowed to stir overnight. The resin was then washed successively with 20% aqueous DMF, DMF, THF, iPrOH, ACOH and dichloromethane.
Figure imgf000052_0001
Step B: Preparation of the Resin-Bound Cyanobenzenesulfonamide . The above resin from Step A was treated with 3 mL of pyridine and 5 g of 4-cyanobenzenesulfonyl chloride in 30 mL dichloromethane and the reddish suspension was allowed to stir overnight. The resin was then washed successively with methanol, AcOH and dichloromethane and a small portion of the resin was cleaved with 1 : 1 dichloromethane/TFA and the purity was checked by HPLC.
Figure imgf000052_0002
Step C: Preparation of the Resin-Bound Amidoxime. The resultant cyano compound from Step B was suspended in 50 mL ethanol and treated with 3.6 g of powdered potassium carbonate and 1.8 g of hydroxylamine hydrochloride and stirred at 75 °C for 16 hrs. A small portion was cleaved as above and checked by HPLC, which indicated the presence of the desired amidoxime and the corresponding amide in a 9: 1 ratio. The resin was washed as above and used to prepare oxadiazoles as shown below.
Figure imgf000053_0001
Step D. Preparation of Resin-Bound Oxadiazoles. A 100-mg portion of the amidoxime resin (0.025 mmole) from Step C and 1 mL diglyme was allowed to swell for 15 min with stirring, and the excess diglyme was drained to the level of the top of resin. To this was added a mixture of 0.25 mmol (10 equiv) of the desired carboxylic acid, 50 mg (0.25 mmol, 10 equiv) of EDC and 1.75 mL of diglyme which had previously been sonicated in a scintillation vial for 20 sec. The tube was covered with a Teflon cover, vented to release excess pressure, and heated on a rack at 99 °C. After 5 minutes, it was vented again. Heating continued for 16 hrs. Diglyme was then drained and the resin was washed successively with DMF, THF/DCM, DCM, and AcOH and dried with a gentle nitrogen blow.
Figure imgf000054_0001
Step E. Oxadiazole Final Products. The resin was treated with 1 : 1 TFA-DCM for 5 minutes. The solvent was drained, and the procedure was repeated. The combined eluants were concentrated to dryness to give the desired oxadiazole as its bistrifluoroacetic acid salt.
Following the procedures outlined for Examples 1-10, the compounds listed in Table 1 were prepared.
TABLE 1
Figure imgf000054_0002
Example R Selected lH NMR (CD3OD) Data
11 3-fluorophenylmethyl, 4.32(s, 2H), 5.22(m, 1H), 7.15- bistrifluoroacetate salt 7.02(m, 6H), 7.38(m, 2H)
12 3,4,5- 4.35(s, 2H), 4.78(m, IH), 7.20(m, trifluorophenylmethyl 2H) 3-chlorophenylmethyl, 4.30(s, 2H), 5.20(m, IH), 7.3-7. l(m, bistrifluoroacetate salt 3H)
2-bromophenylmethyl, 4.41(s, 2H), 5.38(m, IH), 7.3-7. l(m, bistrifluoroacetate salt 2H), 7.61(d, IH)
4-methylphenylmethyl, 2.28(s, 3H), 4.27(s, 2H), 5.20(m, bistrifluoroacetate salt lH), 8.10 & 7.83(ea d, ea 2H)
2,4- 4.38(s, 2H), 5.21(m, IH), 7.90(m, difluorophenylmethyl, 2H), 7.5(m, IH) bistrifluoroacetate salt
3,5- 4.40(s, 2H), 7.85(m, 2H), 8.41(m, difluorophenylmethy 1 , IH) bistrifluoroacetate salt
3-pyridylmethyl 4.78(m, IH), 7.36(m, IH), 7.40(m, IH), 7.90(m, IH), 8.49(s, IH)
4-(2- 4.50(s, 2H), 5.20(m, IH), 8.78(m, pyridyl)phenylmethyl, 2H) bistrifluoroacetate salt
4-(3- 4.47(s, 2H), 5.18(m, IH), 9.12(s, pyridyl)phenylmethyl, IH) bistrifluoroacetate salt
3,5- 4.60(s, 2H), 5.22(m, IH), 7.92(s, bis(trifluoromethyl)- IH), 8.06(2, 2H) phenylmethyl, bistrifluoroacetate salt
4-fluoro-3- 4.46(s, 2H), 5.23(m, IH), 7.33(t,
(trifluoromethyl)phenyl IH), 7.7(m, IH), 7.76(d, IH), 8.0(m, methyl, IH) bistrifluoroacetate salt
4-(trifluorornethyl)- 4.47(br s, 2H), 4.7(m, IH), 8.12 & phenylmethyl 7.8(ea d, ea 2H)
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
EXAMPLE 66
Figure imgf000059_0002
-Fluorobenzylamidoxime To a stirred suspension of hydroxyamine hydrochloride (1.5 g, 3 equiv) and potassium carbonate (4.0 g, 4 equiv) in -95% aqueous EtOH (15 mL) was added 4- fluorophenylacetonitrile (1.0 g, 7.4 mmol) in one portion. The resulting mixture was stirred at reflux ovemight. The reaction was quenched with water, and the aqueous mixture was extracted with EtOAc (3X). The combined organic solution was washed with water and brine, dried with Na2S04, and evaporated. The yellow oil residue was purified by flash column chromatography on silica gel, and eluted with 80-90% EtOAc in hexane. The product (300 mg) was isolated as off-white crystalline solid: iH NMR (400 MHz, CDC13) δ 3.41 (s, 2H), 4.48 (broad, 2H), 6.98 (m, 2H), 7.21 (m, 2H), 8.8 (very broad, IH).
EXAMPLE 67
Figure imgf000060_0001
3-(4-Fluorobenzyl)-5-(4-N-tBoc-aminophenyl)- 1.2.4-oxadiazole To a stirred solution of 4-N-tBoc-aminobenzoic acid (425 mg, 1 equiv) in diglyme (3 mL) was added 4- fluorobenzylamidoxime (300 mg, 1.8 mmol) followed by EDC (350 mg, 1 equiv). The reaction was stirred at room temperature ovemight, and then heated to 100°C for 3 hr under nitrogen. After cooling, solvent was evaporated and the residue was purified by flash column chromatography on silica gel, and eluted with 1-2% methanol in dichloromethane. The product (150 mg) was isolated as viscous yellow oil: !H NMR (400 MHz, CDCI3) δ 1.50 (s, 9H), 4.06 (s, 2H), 7.0 (m, 2H), 7.3 (m, 2H), 7.48 (d, J=8.8Hz, 2H), 8.00 (d, J=8.8Hz, 2H). EXAMPLE 68
Figure imgf000061_0001
3-f4-Fluorobenzyl)-5-(4-chlorosulfonylphenyl)- 1 ,2.4-oxadiazole To a stirred solution of the above oxadiazole from Example 67 (150 mg, 0.4 mmol) in dichloromethane (2.5 mL) was added TFA (2.5 mL) in one portion. After 2 hr, solvent and TFA were evaporated under a stream of nitrogen. The solid residue was taken up into concentrated hydrochloric acid (4 mL) and glacial acetic acid (1 mL) with stirring. The resulting mixture was cooled to -10°C, and a solution NaNθ2 (50 mg, 2 equiv) in water (1 mL) was added dropwise so that the reaction temperature was lower than -5 °C. After the addition, the orange colored mixture was stirred for 45 min, and then transferred onto a saturated solution of Sθ2 in glacial AcOH (~4 mL) containing CuCl (100 mg) at 0-10 °C. The resulting olive-green mixture foamed during the addition, and slowly turned yellow. After 40 min. at room temperature, the reaction was poured onto ice-water, and extracted with EtOAc (3X). The combined organic solution was washed with cold water, cold aqueous NaHCθ3, and brine, dried with MgSθ4, and evaporated. The residue was purified by flash column chromatography on silica gel, and eluted with 25% EtOAc in hexane. The product (2.5 mg) was isolated as white solid: iH NMR (400 MHz, CDCI3) δ 4.13 (s, 2H), 7.0 (m, 2H), 7.3 (m, 2H), 8.17 (d, J=8.8Hz, 2H), 8.34 (d, J=8.8Hz, 2H). EXAMPLE 69
Figure imgf000062_0001
(RVN-r4-r2-rr2-Hvdroxy-2-(pyridin-2- yl)ethyllamino1ethynphenyl1-4-r3-(4-fluorobenzyl)-r 1.2.41- oxadiazol-5-yllbenzensulfonamide
To a stirred solution of the above sulfonyl chloride from Example 68 (2.5 mg, 0.007 mmol) in dichloromethane (1 mL) was added (R)-H-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2-(pyrid- 3-yl)ethylcarbamic acid 1,1-dimethylethyl ester (3.6 mg, 1.4 equiv) and pyridine (1 drop). The reaction was stirred at room temperature ovemight. After removing the solvent under reduced pressure, the residue was purified by flash column chromatography on silica gel, and eluted with EtOAc. The tBoc protecting group was then removed by stirring a dichloromethane solution (1 mL) of the compound with TFA (1 mL) at room temperature for 2 hr. Solvent and TFA were removed by a stream of nitrogen, and the residue was purified by flash column chromatography on silica gel, and eluted with 10% methanol (containing 1/10 aqueous ammonium hydroxide) in dichloromethane. The product (2 mg) was isolated as white solid: iH NMR (400 MHz, CD3OD) δ 2.70- 2.90 (m, 6H), 4.12 (s, 2H), 4.82 (m, IH), 7.05 (m, 6H), 7.3-7.4 (m, 3H), 7.82 (m, IH), 7.88 (d, J=8.6Hz, 2H), 8.18 (d, J=8.6Hz, 2H), 8.42 (m, IH), 8.52 (m, IH). EXAMPLE 70
HO-N
3.4-Difluorobenzylamidoxime
Following the procedure outlined in Example 66, the title compound was prepared: iH NMR (400 MHz, CDCI3) δ 3.39 (s, 2H), 4.46 (broad, 2H), 7.0 (m, IH), 7.1 (m, 2H), 7.4 (very broad, IH).
EXAMPLE 71
Figure imgf000063_0001
(RVN-r4-r2-rr2-Hvdroxy-2-(pyridin-2- yl)ethyl]aminolethyllphenyll-4-r3-(3.4-difluorobenzylVπ.2.41- oxadiazol-5-yl]benzensulfonamide
To a stirred solution of (R)-N-[2-[4- (aminophenyl)]ethyl]-2-hydroxy-2-(pyrid-3-yl)ethylcarbamic acid 1,1-dimethylethyl ester (500 mg, 1.4 mmol) and pyridine (0.15 mL, 2 equiv) in diglyme (10 mL) was added 4-chlorosulfonyl benzoic acid (310 mg, 1 equiv). The orange red reaction mixture was stirred at room temperature ovemight. To this mixture was added the above amidoxime from Example 70 (280 mg, 1.1 equiv) followed by DCC (310 mg, 1.1 equiv), and stirring was continued at room temperature for another day. The reaction was then heated to 100°C for 3 hr. After removing the solvent in vacuo, the residue was purified by flash column chromatography on silica gel, and eluted with EtOAc. The tBoc protecting group was then removed by stirring a dichloromethane solution (2.5 mL) of the compound with TFA (2.5 mL) at room temperature for 2 hr. Solvent and TFA were removed by a stream of nitrogen, and the crude product was purified by flash column chromatography on silica gel, and eluted with 10% methanol (containing 1/10 aqueous ammonium hydroxide) in dichloromethane. The product (180 mg) was isolated as light yellow solid: iH NMR (400 MHz, CD3OD) δ 2.70-2.90 (m, 6H), 4.13 (s, 2H), 4.8 (m, IH), 7.0-7.4 (m, 8H), 7.8 (m, IH), 7.88 (d, J=8.6Hz, 2H), 8.18 (d, J=8.6Hz, 2H), 8.42 (m, IH), 8.51 (m, IH).
EXAMPLE 72
Figure imgf000064_0001
(RVN-r4-r2-rr2-Hvdroxy-2-(pyridin-3- yl)ethyllaminolethynphenyl1-4-(5-phenylamino-π.2.41-oxadiazol- 3-yl)benzenesulfonamide
To a solution of the amidoxime from Example 2 (100 mg, 0.18 mmol) and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (30mg, 0.20mmol) in anhydrous dichloromethane (20 ml) under nitrogen at 0 °C, phenylisocyanide dichloride (31 mg, 0.18 mmol) was added slowly. The resulting solution was allowed to stir at 0 °C for 30 min. and then warm to room temperature and stir ovemight. The crude product was purified by silica gel prep TLC(8% methanol/dichloromethane, containing 1% aqueous ammonium hydroxide). The resultant Boc derivative was treated with 50% trifluoroacetic acid in dichloromethane and then concentrated. The product was purified by silica gel prep TLC (12% methanol/dichloromethane, containing 1% aqueous ammonium hydroxide) to provide 19.0 mg (19%) of the title product: H NMR (CD3OD) δ 8.54 (d, J=1.75 Hz, IH), 8.43 (dd, J=4.98, 1.34 Hz, IH), 8.13 (d, J=8.44 Hz, 2H), 7.84 (d, J=8.43 Hz, 2H), 7.83 (m, IH), 7.63 (d, J=7.61 Hz, 2H), 7.40 (m, IH), 7.36 (t, J=6.74 Hz, 2H), 7.12 (d, J=8.58 Hz, 2H), 7.09 (m, IH), 7.06 (d, J=8.53 Hz, 2H), 4.84 (m, IH), 2.93 (m, 4H), 2.81 (t, J=7.47 Hz, 2H).
EXAMPLE 73
Figure imgf000065_0001
(R)-N-,4-.2-,T2-Hydroxy-2-(pyridin-3- yl)ethyllamino1ethyllphenyn-4-r5-(4-fluorophenyl)amino-ri.2.41- oxadiazol-3-yl1benzenesulfonamide
Following the procedure outlined in Example 72, the title compound was prepared: Selected iH NMR Data (CD3OD) δ 7.63(m, 2H), 7.10(m, 2H). EXAMPLE 74
Figure imgf000066_0001
(RVN-r4-r2-rr2-Hvdroxy-2-(pyridin-3- vDethyllamino1ethyl1phenyll-4-r3-f4-fluorophenoxymethyl)- f 1.2.41-oxadiazol-5-yl1benzenesulfonamide
Following the procedures outlined in Examples 70-71, the title compound was prepared: Selected iH NMR Data (CD3OD) δ 8.51 (m, IH), 8.41 (m, IH), 8.24 (d, J = 8.6 Hz, 2H), 7.91 (d, J = 8.6 Hz, 2H), 7.81 (m, IH), 7.09 (d, J = 8.53, 2H), 7.06- 7.00 (m, 6H), 5.25 (s, 2H).
Following the procedures outlined for Examples 1-10, the compounds listed in Table 2 were prepared.
TABLE 2
Figure imgf000066_0002
Example Selected iH NMR (CD3OD) Data 4- 8.08 (m, 2H), 7.22 (d, 2H), 5.27 (m, trifluoromethoxypheno 2H), 5.49 (s, 2H) xymethyl, bistrifluoroacetate salt
4- 8.05 (m, 2H), 7.48 (d, 2H), 5.28 (m, trifluoromethoxyphenyl 2H), 4.40 (s, 2H) methyl, bistrifluoroacetate salt
EXAMPLE 77
Figure imgf000067_0001
(R)-N-r4-r2-rr2-Hvdroxy-2-(pyridin-3- yl ethyl1amino1ethyllphenvn-4-r5-ri-f4-fluorophenyl)-l- methoxymethyll-r 1.2.41-oxadiazol-3-yllbenzenesulfonamide Step A. Methyl 4-Fluoromandelate. 4-Fluoromandelic acid (2.53 g) in 10 ml of THF was treated with excess diazomethane etherate (generated from N-methyl-N-nitrosourea and aqueous potassium hydroxide at 0 C). The reaction mixture was concentrated in vacuo, and the residue was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The title compound (2.70 g) was isolated as an oil after drying and evaporation: Selected H NMR (400 MHz, CDCI3) δ 3.08 (s, 3H) and 3.75 (s, 3H). Step B. Methyl ( -Fluorophenyl)methoxyacetate. Sodium hydride (585 mg, 60% oil dispersion) was added in portions to a stirred solution of 2.02 g methyl 4-fluoromandelate obtained above in a mixture of 18 mL of THF and 3 mL of DMF at 0 °C. After 10 min, iodomethane (1.95 mL, 3 equiv) was added and the mixture was allowed to warm up to room temperature and stir for 0.5 h. After evaporation and extraction with ethyl acetate, the organic phase was washed with water and brine, dried over magnesium sulfate, and the residue obtained after filtration and evaporation was purified by flash chromatography on silica column (20% ethyl acetate/hexane), affording 1.01 g of the title compound: iH NMR (400 MHz, CDC13) δ 7.43-7.37 (m, 2H), 7.08-7.0 (m, 2H), 4.73 (s, IH), 3.78 (s, 3H), 3.70 (s, 3H). Step C. (4-FluorophenyPmethoxyacetic acid. The above methyl ether methyl ester (1.01 g) and 3.67 mL of 2N aqueous sodium hydroxide in 14 mL of methanol at 0 °C was stirred at room temperature for 2 h. The mixture was evaporated, chilled in ice, acidified with 2N aqueous hydrochloric acid, extracted with ethyl acetate, washed with water and brine, and dried with magnesium sulfate. Evaporation yielded the corresponding carboxylic acid (1.0 g): Selected iH NMR (400 MHz, CDCI3) δ 3.70 (s, 3H). Step P. (R)-N-r4-r2-rN-(l.l-Dimethylethoxycarbonvn-N-r2- hvdroxy-2-(pyridin-3-yl)ethynamino1ethyπphenyll-4-r5-fl-(4- fluorophenyl 1 -methoxymethyll-r 1.2.41-oxadiazol-3- yllbenzenesulfonamide. To a stirred mixture of equimolar molar quantities of the carboxylic acid from Step C (438 mg, 2.38 mmol) and the amidoxime from Example 2 (1.32 g, 2.38 mmol) in 14.3 mL of THF at room temperature under nitrogen was added EDC (456 mg, 2.38 mmol) in portions. The resultant mixture was stirred at ambient temperature for 16 h, and then heated at 50 °C for 1.5 h. The solvent (THF) was removed by evaporation and replaced with an equal volume of dry pyridine. The mixture was refluxed for 5 h, evaporated to an oil and purified by preparative TLC (Siθ2 plates) in 90:9: 1 dichloromethane: methanol: aqueous ammonium hydroxide to give 881 mg of the title compound: iH NMR (400 MHz, CDC13) δ 8.48 (br s, 2H), 8.11 (d, J = 8.45 Hz, 2H), 7.79 (d, J = 8.45 Hz, 2H), 7.69 (br s, IH), 7.51-74.7 (m, 2H), 7.3-7.25 (m, IH), 7.11-7.02 (m, 2H), 6.96 (br s, 4H), 5.57 (s, IH), 4.89-4.82 (br s, IH), 4.63-4.55 (br s, IH), 3.47 (s, 3H), 3.44-3.06 (m, 4H), 2.83- 2.57 (m, 3H), 1.41 (s, 9H). Step E. (R -N-r4-r2-rr2-hvdroxy-2-(pyridin-3- y ethvnamino1ethyl1phenyll-4-r5-r 1 -(4-fluorophenyl 1 - methoxymethyll-f 1.2.41-oxadiazol-3-yllbenzenesulfonamide. The above N-Boc compound from Step D was deprotected with 24 mL of trifluoroacetic acid in 36 mL of dichloromethane at 0 °C and at ambient temperature ovemight. The mixture was evaporated and treated with 1 mL of 10% aqueous ammonium hyroxide in methanol and then the final residue obtained after evaporation was purified by preparative TLC (90:9: 1 dichloromethane: methanol: aqueous ammonium hydroxide) to give 670 mg of the title compound: iH NMR(400 MHZ, CDCI3) δ 8.51
(br s, IH), 8.47-8.46 (m, IH), 8.09 (d, J = 8.49 Hz, 2H), 7.80 (d, J = 8.49 Hz, 2H), 7.65 (m, IH), 7.5-7.42 (m, 2H), 7.28-7.20 (m, IH), 7.10-6.93 (m, 6H), 5.56 & 5.54 (2s, IH), 5.02 (m, J = 6.37 Hz, IH), 4.8-4.65 (m, IH), 3.45 & 3.44 (2s, 3H), 3.35-3.26 (m, 2H), 2.9- 2.75 (m, 2H), 2.75-2.55 (m, 4H).
Following the procedures outlined for Examples 1-10 and 77, the compounds listed in Table 3 were prepared.
TABLE 3
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000071_0001
Figure imgf000072_0001
105 4- CD3OD, 8.41 (d, J = 8.0 Hz, 2H). trifluoromethylpheny 1 , 8.00-7.85 (m, 5H) bistrifluoroacetate salt
106 4- CD3OD, 8.32 (d, J = 8.9 Hz, 2H), trifluoromethoxyphenyl 7.53 (d, J = 8.0 Hz, 2H)
107 3,4,5-trifluorophenyl CD3OD, 8.01 (t, J = 6.8 Hz, 2H)
108 6-fluoronaphth-2- CD3OD, 7.90 (m, IH), 7.79 (d, J = yloxymethyl, 9.1 Hz, I H), 7.50-7.40 (m, 2H), bistrifluoroacetate salt 7.32-7.21 (m, 2H), 5.57 (s, 2H)
109 6-fluoronaphth-2- CD3OD, 7.90-7.75 (m, 6H), 7.50 ylmethyl ( , 2H), 7.28 (m, IH), 4.49 (s, 2H)
EXAMPLE 1 10
Figure imgf000073_0001
(RVN-l4-[2-H2-Hvdroxy-2-{pyridin-3- vDeth yl laminolethyl lphenyl 1-4-15-11 -fluoro- 1 -(4- trifluoromethylphen yl methyll-f 1.2.41-oxadiazol-3- yl 1 benzenesulfonamide
Step A. Methyl 4-trifluoromethylphenylacetate. A colorless solution of 4-trifluorophenylacetic acid (2.00 g, 9.8 mmol) in methanol (5 L) containing concentrated H2SO4 (0.5 mL) was heated at reflux for 3 h. After cooling to RT, the volume of methanol was reduced in vacuo. Ice was added and the mixture extracted with diethyl ether (3X). The combined organic phase was washed with water, saturated NaHC03 solution (4X), water, brine, dried (MgSθ4) and the solvent removed in vacuo to leave 1.98 g (93%) of the title compound as a colorless liquid: * H NMR (300 MHz, CDC13) δ 7.58 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 3.71 (s, 3H), 3.69 (s, 2H). Step B. Methyl 2-fluoro-2-(4-trifluoromethylphenyl)acetate. A 1.0M solution of lithium bis(trimethylsilyl)amide in THF ( 1.97 mL, 1.97 mmol) was added to a stirred solution of the ester from Step A (391 mg, 1.79 mmol) in THF (4 ml) at -78 °C. The yellow solution was stirred at -78 °C for 10 min. A precooled solution of N-fluorobenzenesulfonimide (593 mg, 1.88 mmol) in THF (4 mL) was added dropwise via a cannular. The off-white suspension was allowed to warm slowly to RT over 12 h. Saturated NH4CI solution was added and the mixture extracted with diethyl ether (3X). The combined organic phase was washed with water (2X), brine, dried (MgSθ4) and the solvent removed in vacuo. Flash chromatography (silica, 30% DCM-hexanes) afforded the title compound (270 mg, 64%) as a pale yellow liquid: iH NMR (400 MHz, CDCI3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.1 Hz, 2H), 5.85 (d, J = 47 Hz, I H), 3.78 (s, 3H). Step C. 2-Fluoro-2-(4-trifluoiOmethylphenyl)aeetic acid. A solution of the ester from Step B (270 mg, 1.15 mmol) in methanol (10 mL) containing 5N NaOH solution (1 mL) was stirred at RT for 12 h. The volume of methanol was reduced to -10% in vacuo. 5% Citric acid solution was added and the mixture extracted with ethyl acetate (4X). The combined organic phase was washed with water (2X), brine, dried (MgS04) and the solvent removed in vacuo to leave the title compound (266 mg, 100%) as an off-white solid: iH NMR (300 MHz, CD3OD) δ 7.73 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 5.99 (d, J = 48 Hz, IH). Step D. (R)-N-f4-l2-rr2-Hvdroxy-2-(pyridin-3- yl ethyllamino1ethyl1phenyll-4-r5-l 1 -fluoro- 1 -(4- trifluoromethylphenyl)methyll-π .2.41-oxadiazol-3- yl Ibenzenesulfonamide. The title compound was prepared as described above for Example 3 using the acid from Step C: iH NMR (400 MHz, CD3OD) δ 8.51 (d, J = 2.1 Hz, 1H), 8.42 (dd, J = 4.9, 1.6 Hz, IH), 8.14 (d, J = 8.7 Hz, 2H), 7.84 (d, J = 8.6 Hz, 2H), 7.81 (m, I H), 7.79 (s, 4H), 7.38 (dd, J = 7.9, 4.9 Hz, IH), 7.08 (d, J = 8.5 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 4.79 (m, IH), 2.95- 2.70 (m, 6H).
EXAMPLE 11 1
Figure imgf000075_0001
rRVN-f4-l2-fT2-Hvdroxy-2-(pyridin-3- vDethyl laminolethyllphenyll-4-r5-i 1 -(4-trifluoroιnethylphenyl)- 1 - ethyll-ri .2.41-oxadiazol-3-yllbenzenesulfonamide Step A. Methyl 2-methyl-2-(4-trifluoromethylphenyl)acetate. A 1.OM solution of lithium bis(trimethylsilyl)amide in THF (2.02 mL, 2.02 mmol) was added to a stirred solution of the ester from Example 110, Step A (400 mg, 1.83 mmol) in THF (8 ml) at -78 °C. The solution was stirred at -78 °C for 10 min. Methyl iodide (120 μL, 1.93 mmol) was added. The solution was allowed to warm slowly to RT over 12 h. Saturated NH4CI solution was added and the mixture extracted with diethyl ether (3X). The combined organic phase was washed with water (2X), brine, dried (MgSθ4) and the solvent removed in vacuo. Flash chromatography (silica, 2- 3% ethyl acetate-hexanes) afforded the title compound (234 mg, 55%) as a colorless liquid: Η NMR (400 MHz, CDCI3) δ 7.56 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.3 Hz, 2H), 3.77 (q, J = 7.1 Hz, IH), 3.66 (s, 3H), 1.50 (d, .1 = 7.1 Hz, 3H). Step B. 2-Methyl-2-(4-trifluoromethylphenyl)acetic acid. A solution of the ester from Step A (234 mg, 1.01 mmol) in methanol (10 mL) containing 5N NaOH solution (1 mL) was stirred at RT for 12 h. The volume of methanol was reduced to -10% in vacuo. 5% Citric acid solution was added and the mixture extracted with ethyl acetate (3X). The combined organic phase was washed with water (2X), brine, dried (MgS04) and the solvent removed in vacuo to leave the tide compound (213 mg, 97%) as an off-white solid: iH NMR (300 MHz, CD3OD) δ 7.60 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 3.82 (q, J = 7.1 Hz, IH), 1.55 (d, J = 7.2 Hz, 3H).
Step C. (R)-N- 4-r2-ir2-Hvdroxy-2-(pyridin-3- yl)ethvnamino1ethvnphenvn-4-r5-ri-(4-trifluoromethylphenyl)-l- ethyl1-π.2.41-oxadiazol-3-yllbenzenesulfonamide. The title compound was prepared as described above for Example 3 using the acid from Example Step B: *H NMR (400 MHz, CD3OD) δ 8.51 (d, J = 2.1 Hz, IH), 8.42 (dd, J = 4.9, 1.6 Hz, IH), 8.14 (d, J = 8.5 Hz, 2H), 7.84 (d, J = 8.6 Hz, 2H), 7.81 (m, IH), 7.65 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 7.37 (dd, J = 7.9, 5.0 Hz, IH), 7.08 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 4.79 (dd, J = 7.6, 5.2 Hz, IH), 4.66 (q, J = 7.1 Hz, IH), 2.91-2.68 (m, 6H), 1.79 (d, J = 7.2 Hz, 3H).
Following the procedures outlined for Examples 1-10, 77, and 110-111, the compounds listed in Table 4 were prepared.
TABLE 4
Figure imgf000077_0001
Figure imgf000077_0002
Figure imgf000078_0001
Following the procedures outlined for Examples 66- , the compounds listed in Table 5 were prepared.
TABLE 5
Figure imgf000079_0001
Example R Selected iH NMR Data (CD3OD)
125 4- 8.34-8.31 (m, 4H), 7.89-7.86 (m, 3) trifluoromethylphenyl, trifluoroacetate salt
126 4- 8.25 (d, J = 9.0 Hz, 2H), 7.49-7.46 tri fl uoromethoxy phenyl (m, 3H)
, trifluoroacetate salt

Claims

WHAT IS CLAIMED IS:
1. A compound having the formula I:
Figure imgf000080_0001
wherein X is (1) a bond,
(2) C1-C3 alkylene optionally substituted with 1 or 2 groups selected from methyl, C ] -C5 alkoxy, hydroxy, and halogen,
(3) C1-C3 alkylene optionally substituted with 1 or 2 groups selected from methyl, C 1 -C5 alkoxy, hydroxy, and halogen, wherein said alkylene contains up to two groups selected from Q and carbonyl,
(4) carbonyl, or
(5) Q; m is 0 to 5; A is (1) phenyl,
(2) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(3) a benzene ring fused to a C5-C10 carbocyclic ring,
(4) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or (5) a 5 or 6-membered heterocyclic ring with from
1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a C5-C10 carbocyclic ring;
(1) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen,
(c) cyano,
(d) QR2,
(e) C3-C8 cycloalkyl,
(f) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-
C 10 alkoxy,
(g) Q'COR3,
(h) S(0)nR3, where n is 0 to 2,
Figure imgf000081_0001
(2) C3-C8 cycloalkyl,
(3) oxo,
(4) halogen,
(5) cyano,
(6) QR2,
(7) S(0)nR3, where n is 0 to 2„
(8) Q'COR3,
(9) NR2S02R3,
(10) NR Cθ2R2,
(11) A optionally substituted with up to 5 groups independently selected from
(a) R2,
(b) QR2,
(c) halogen, and
(d) oxo; or
(12) CO2R2; R2 is (1) hydrogen,
(2) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy, (b) halogen,
(c) CO2R4,
(d) S(O)n-Cl-C10 alkyl, where n is 0 to 2,
(e) C3-C8 cycloalkyl,
(f) C l -C 10 alkoxy, and (g) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy,
(3) C3-C8 cycloalkyl, or
(4) A optionally substituted with up to 5 groups selected from
(a) halogen,
(b) nitro,
(c) oxo,
(d) NR4R4, (e) Cl-C 10 alkoxy,
(f) S(0)n-C l -C 10 alkyl, where n is 0 to 2, and
(g) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, CO2R4, S(0)n-Cl -C 10 alkyl, where n is 0 to 2,
C3-C8 cycloalkyl, Cl-C 10 alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Ci- C 10 alkoxy; R is (1) R2 or
(2) NR2R2; R4 is (1) H, or
(2) C1-C10 alkyl; Q is (1) N(R2), (2) O or
0) S(0)n, and n is 0 to 2;
Q' is (1) N(R2),
(2) O or
(3) a bond; or a pharmaceutically acceptable salt thereof.
2. A compound of Claim 1 wherein X is C1-C3 alkylene optionally substituted with one or two groups selected from methyl, and halogen.
3. A compound of Claim 1 wherein X is C1-C3 alkylene-O-, C1-C3 alkylene-carbonyl, carbonyl or N(R2) wherein the alkylene is optionally substituted with one or two groups selected from methyl and halogen.
4. A compound of Claim 1 wherein X is selected from the group consisting of -CH2-, -CH(CH3)-, -C(CH3)2-, -CHF-, -CH20-, and -C(CH3)2θ-.
5. A compound of Claim 1 having the formula Ia:
Figure imgf000083_0001
Ia
A compound of Claim 1 having the formula lb:
Figure imgf000084_0001
lb
7. A compound of Claim 1 wherein
A is (1) phenyl,
(2) naphthyl,
(3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.
8. A compound of Claim 1 wherein Rl i is ( 1 ) C 1 -C 10 alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen,
(c) cyano,
(d) QR2,
(e) C3-C8 cycloalkyl,
(f) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy,
(g) Q'COR3,
(h) S(0)nR3, where n is 0 to 2, (i) NR2S02R3, and (j) NR2Cθ2R2, (2) halogen,
(3) QR2,
(4) S(0)nR3, where n is 0 to 2,
(5) Q'COR3, (6) phenyl optionally substituted with up to 4 groups independently selected from
(a) R2,
(b) QR2 and
(c) halogen, or (7) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups independently selected from
(a) oxo, (b) R2,
(c) QR2 and
(d) halogen.
9. A compound of Claim 1 wherein A is (1) phenyl,
(2) naphthyl,
(3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or (4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; Rl is (1) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from (a) hydroxy,
(b) halogen,
(c) cyano,
(d) QR2,
(e) C3-C8 cycloalkyl, (f) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy,
(g) Q'COR3, (h) SO2R3,
(i) NR Sθ2R3, and (j) NR2Cθ2R2,
(2) halogen,
(3) QR2, (4) SO2R3,
(5) Q'COR3,
(6) phenyl optionally substituted with up to 4 groups independently selected from
(a) R2, (b) QR2 and
(c) halogen, or
(7) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups independently selected from
(a) oxo,
(b) R2,
(c) QR2 and
(d) halogen.
10. A compound of Claim 1 wherein A is (1) phenyl,
(2) naphthyl,
(3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, or
(4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; Rl is (1) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from
(a) hydroxy,
(b) halogen, (c) cyano,
(d) QR2,
(e) C3-C8 cycloalkyl,
(f) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-ClO alkoxy,
(g) Q'COR3, (h) SO2R3,
(i) NR2Sθ2R3, and (j) NR2Cθ2R2, (2) halogen,
(3) QR2,
(4) SO2R3,
(5) Q'COR3,
(6) phenyl optionally substituted with up to 4 groups independently selected from
(a) R2,
(b) QR2 and
(c) halogen, or
(7) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups independently selected from
(a) oxo,
(b) R2 (c) QR2 and
(d) halogen; R2 is (1) hydrogen
(2) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from (a) hydroxy,
(b) halogen,
(c) C02R4,
(d) S(0)n-C 1 -C 10 alkyl, where n is 0 to 2, (e) C3-C8 cycloalkyl,
(f) Cl-C 10 alkoxy, and
(g) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl- C 10 alkoxy, (3) A optionally substituted with up to 5 groups selected from
(a) halogen,
(b) nitro,
(c) oxo, (d) NR R4,
(e) Cl-C 10 alkoxy,
(f) Cl-C 10 alkylthio, and
(g) C 1 -C 10 alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, CO2R4, S(O)n-Cl-Cl0 alkyl, where n is 0 to 2,
C3-C8 cycloalkyl, Cl-ClO alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl- C 10 alkoxy; Q is (1) N(R2),
(2) O or
(3) S.
11. A compound of Claim 1 wherein A is (1) phenyl,
(2) naphthyl,
(3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, (4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; Rl is (1) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from
(a) halogen,
(b) cyano,
(c) QR2,
(d) A optionally substituted with up to 5 groups selected from halogen, C l -C 10 alkyl and
Cl-C 10 alkoxy,
(2) halogen,
(3) phenyl optionally substituted with up to 4 groups independently selected from (a) R2,
(b) QR2 and
(c) halogen, or
(4) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups independently selected from
(a) R2,
(b) QR2 and
(c) halogen, (5) QR2;
R2 is (1) Cl-ClO alkyl optionally substituted with up to 5 groups selected from
(a) halogen,
(b) C l -C 10 alkoxy, and (c) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy,
(2) A optionally substituted with up to 5 groups selected from (a) halogen,
(b) NR4R4,
(c) Cl-C 10 alkoxy,
(d) C 1 -C 10 alkylthio, and (e) Cl-C 10 alkyl optionally substituted with up to 5 groups selected from halogen, C3-C8 cycloalkyl, Cl-C 10 alkoxy, and A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-C 10 alkoxy; Q is (1) N(R2),
(2) O or
(3) S.
12. A compound of Claim 11 wherein A is phenyl.
13. A compound of Claim 11 wherein X is CH2 or CH2O wherein oxygen is attached to the A moiety.
14. A compound of Claim 1 wherein
X is (1) CH2
(2) CH2θ wherein oxygen is attached to the A moiety,
A is (1) phenyl,
(2) naphthyl,
(3) a 5 or 6-membered heterocyclic ring with f
1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen,
(4) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen;
R 1 is ( 1 ) C 1 -C 10 alkyl optionally substituted with up to 5 groups selected from (a) halogen, (b) A optionally substituted with up to 5 groups selected from halogen, Cl-C 10 alkyl and Cl-
ClO alkoxy,
(2) halogen, (3) 5 or 6-membered heterocycle with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to 4 groups selected from halogen, R2 and QR2,
(4) QR2; R2 is C 1 -Cl 0 alkyl, optionally substituted with up to 5 halogen atoms; Q is O.
15. A compound selected from the group consisting of:
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(5-methylisoxazol-3-yl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(4-fluorophenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-fluorophenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(2,5-difluorophenyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3,5-difluorophenyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-trifluoromethylphenyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-nitrophenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methylthiophenyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methylsulfonylphenyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(2-methylphenyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methylρhenyl)-[ 1 ,2,41-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-methoxyphenyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]ρhenyl]-4- [5-(3-pyridyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4- [5-(2,3-dimethoxyphenyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(2-benzofuranyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(5-fluoro-2-indolyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[2-(4-fluorophenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[2-(3,4-difluorophenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[2-(4-methoxyphenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[2-(phenyl)ethyl]-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[2-(4-chlorophenyl)ethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N- [4- [2- [ [2-hy droxy-2- (3-pyridiny l)ethy 1] amino] ethy 1] pheny l]-4- [5-[3-(phenyl)propyl]-[l,2,4]-oxadiazol-3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[3-(4-methoxyρhenyl)propyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-fluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-fluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-chlorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4-difluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4,5-trifluorophenylmethyl)-[ 1 ,2,41-oxadiazol-3- yl]benzensulfonamide,
N- [4- [2- [ [2-hy droxy-2-(3 -pyridinyl)ethy 1] amino]ethyl]pheny 1] -4- [5-[3,5-bis(trifluoromethyl)ρhenylmethyl]-[l,2,4]-oxadiazol-3- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-[l,2,4]-oxadiazol-
3-yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[[4-(trifluoromethyl)phenyl]methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[[4-(methylthio)phenyl]methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[[4-(methylsulfonyl)phenyl]methyl]-[ 1 ,2,41-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(biphen-4-ylmethyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyllaminolethyl]phenyl]-4-
[5-[4-(2-pyridyl)phenylmethyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[4-(3-pyridyl)phenylmethyl]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[(4-acetamido)phenylmethyl]-[l ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-chlorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-bromophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5- (4-methy lpheny lmethyl)- [ 1 ,2 ,4]-oxadiazol-3 - yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,4-difluorophenylmethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyllaminolethyl]phenyl]-4- [5-(3,5-difluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-pyridylmethyl)-[ 1 ,2,4]-oxadiazol-3-yllbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-indolylmethyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-naphthylmethyl)-[l,2,4]-oxadiazol-3-yllbenzensulfonamide, - 93
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[(5-fluoro-3-indolyl)methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3-thienylmethyl)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyll-4-
[5-[(5-chlorobenzo[b]thien-3-yl)methyl]-[l,2,4]-oxadiazol-3- yllbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4- [5-[(benzo[b]thien-3-yl)methyl]-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[(2,3-dihydrobenzofuran-5-yl)methyl]-[l,2,4]-oxadiazol-3- yllbenzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-oxo-3-(4-fluorophenyl)propyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-(naphthyloxy)methyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-fluorophenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3,4-difluorophenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-acetamidophenoxymethyl)-[l,2,41-oxadiazol-3- yljbenzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-trifluoromethylphenoxymethyl)-[l,2,41-oxadiazol-3- yl]benzensulfonamide, N- [4- [2- [ [2-hy droxy-2-(3-pyridiny l)ethy l]amino]ethyl]phenyl] -4-
[5-(4-tetrazol-5-ylphenoxymethyl)]-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(4-acetyloxyphenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-methylphenoxymethyl)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-phenoxyethyl)-[ 1 ,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(phenylamino)-[l,2,4]-oxadiazol-3-yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]aminolethyl]phenyl]-4- [5-(4-fluorophenylamino)-[l,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyll-4-
[3-(3,4-difluorophenylmethyl)-[l,2,4]-oxadiazol-5- yl]benzensulfonamide, N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[3-(4-fluorophenylmethyl)-[ 1 ,2,4]-oxadiazol-5- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4-methylenedioxyphenylmethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-fluorophenylcarbonyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(4-chlorophenylcarbonyl)-[l ,2,41-oxadiazol-3- y 1] benzensulf onamide
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyllaminoJethyl]phenyl]-4-
[3-(4-fluorophenoxymethyl)-[l,2,41-oxadiazol-5- yllbenzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-trifluoromethoxyphenoxymethyl,)-[l,2,4]-oxadiazol-3- yljbenzensulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4- [5-(4-trifluoromethoxyphenylmethyl)-[l ,2,4]-oxadiazol-3- yl]benzensulfonamide,
N- [4- [2- [ [2-hydroxy-2- (3-py ridinyl)ethy 1] amino] ethyl] pheny l]-4-
[5- [ 1 -(4-fluorophenyl)- 1 -methoxymethyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[ l-(3,4-difluorophenyl)- 1 -methoxymethyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[ 1 -(4-fluorophenyl)- 1 -ethoxymethyl]-[ 1 ,2,4]-oxadiazol-3- yllbenzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5- [ 1 -(4-chlorophenyl)- 1 -methoxymethyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4- [5-[l-(4-chlorophenyl)-l-ethoxymethyl]-!l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-!2-[f2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyllphenyl]-4-
[5-(2-naphthyl)-[l,2,41-oxadiazol-3-yllbenzenesulfonamide,.
N-f4-f2-ff2-hydroxy-2-(3-pyridinyl)ethyllaminolethyllphenyll-4- [5-(6-quinolinyl)-!l,2,4]-oxadiazol-3-yl]benzenesulfonamide,
N-r4-f2-[r2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3-methoxyphenoxymethyl)-fl,2,41-oxadiazol-3- yllbenzenesulfonamide,
N-f4-[2-ff2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyllphenyll-4- [5-(3-chlorophenoxymethyl)-ll,2,41-oxadiazol-3- yl] benzenesulfonamide,
N-f4-f2-f!2-hydroxy-2-(3-pyridinyl)ethyl1aminolethyllphenyl1-4- f 5-(4-isopropylρhenoxymethyl)-f 1 ,2,4]-oxadiazol-3- yllbenzenesulfonamide, N-f4-!2-ff2-hydroxy-2-(3-pyridinyl)ethyllaminolethyl]phenyll-4-
[5-(4-chlorophenoxymethyl)-[l,2,41-oxadiazol-3- yllbenzenesulfonamide,
N-!4-[2-ff2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(3,4-dichlorophenoxymethyl)-fl,2,4]-oxadiazol-3- y 1 ] benzenesulfonamide ,
N-f4-f2-r[2-hydroxy-2-(3-pyridinyl)ethyllaminolethyllphenyll-4-
[5-(4-tert-butylphenoxymethyl)-[l,2,41-oxadiazol-3- yllbenzenesulfonamide, N-r4-!2-r!2-hydroxy-2-(3-pyridinyl)ethyllaminolethyl]phenyl]-4-
!5-(4-sulfonamidophenoxymethyl)-f 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-!2-f!2-hydroxy-2-(3-pyridinyl)ethyllamino1ethyllphenyl1-4- f5-(3-chloronaphthyl- 1 -yloxymethyl)-f 1 ,2,41-oxadiazol-3- yllbenzenesulfonamide,
N-[4-12-[f2-hydroxy-2-(3-ρyridinyl)ethyl1aminolethyl]phenyll-4-
[5-(5-indanyloxymethyl)-f l,2,41-oxadiazol-3- y 11 benzene sulfonamide,
N-!4-[2-[!2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]ρhenyl]-4- r5-(4-indanyloxymethyl)-! 1 ,2,4]-oxadiazol-3- y 1] benzenesulfonamide ,
N-f4-f2-ff2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- f5-(2-chlorophenoxymethyl)-! 1 ,2,41-oxadiazol-3- yll benzenesulf onamide , N-r4-[2-[f2-hydroxy-2-(3-pyridinyl)ethyllaminolethyl]phenyll-4-
[5-(3,5-dichlorophenoxymethyl)-[l,2,41-oxadiazol-3- yllbenzenesulfonamide,
N-f4-!2-ff2-hydroxy-2-(3-pyridinyl)ethyllaminolethyl]phenyl1-4-
[5-(3-trifluoromethoxyphenoxymethyl)-f l,2,41-oxadiazol-3- yllbenzenesulfonamide,
N-!4-!2-rr2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-14-(l,2-benzisoxazol-3-yl)-2,3-dichlorophenoxymethyl]-f 1,2,4]- oxadiazol-3-yl]benzenesulfonamide, N- [4- !2- ! [2-hy droxy-2- (3 -pyridinyl )ethy 1] amino]ethy l]pheny 1] -4-
[5-(2,4-dichlorophenoxymethyl)-f 1 ,2,4]-oxadiazol-3- yllbenzenesulfonamide,
N-[4_ 2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5- [4- (2-quinazoliny l)phenoxy methy 11 - [1,2 ,4] -oxadiazol- 3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,4,5-trichlorophenoxymethyl)-[l,2,4]-oxadiazol-3- yllbenzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2,3-dichlorophenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-ρyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(2-chioro-4-tert-butylphenoxymethyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-[2,3-dichloro-4-(2-thienylsulfonyl)phenoxymethyl]-[ 1 ,2,4]- oxadiazol-3-yl]benzenesulfonamide,
N-r4-[2-[r2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-[4-(N,N-dipropylsulfamoyl)phenoxymethyl]-[ 1 ,2,4]-oxadiazol-
3-yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-trifluoromethylphenyl)-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(4-trifluoromethoxyphenyl)-[l,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(3,4,5-trifluorophenyl)-[l,2,4]-oxadiazol-3- yllbenzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-
[5-(6-fluoronaphth-2-yloxymethyl,)-[l,2,4]-oxadiazol-3- yllbenzenesulfonamide, N-[4-f2-[f2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4- [5-(6-fluoronaphth-2-ylmethyl,)-[ 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-[4-r2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4- [5-[ 1-fluoro- 1 -(4-trifluoromethylphenyl)methyl]-[ 1 ,2,4]-oxadiazol- 3-yllbenzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[ 1 -(4-trifluoromethylphenyl)- 1 -ethyl]-[ 1 ,2,4]-oxadiazol-3- y 1 ] benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyllphenyl]-4- [5-[]-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[]-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4- [5-[]-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[l-[l,2,4]-oxadiazol-3-yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[l-(4-fluorophenoxy)-l-methylethyll-[l ,2,4]-oxadiazol-3- yllbenzenesulfonamide,
N-[4-[2-r[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[l-(l-naphthyloxy)-l-methylethyl]-[l,2,4]-oxadiazol-3- yl ] benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[l-(2-naphthyloxy)-l-methylethyl]-[l,2,4]-oxadiazol-3- y 1 ] benzenesulfonamide,
N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5- [l-(4-chlorophenoxy)- 1-methylethyl]- [1, 2,4]-oxadiazol-3- yl]benzenesulfonamide, N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-[ 1 -(2-chlorophenoxy)- 1 -methylethyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-!4-!2-![2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
15-[ 1 , 1 -difluoro- 1 -(phenyl)methyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-[4_[2-ϋ2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- [5-r 1 -(4-(4-chlorophenyl)phenoxy)- 1 -methylethyl]-! 1 ,2,4]- oxadiazol-3-yl]benzenesulfonamide,
N-f4-f2-!f2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]ρhenyl]-4-
!5-! 1 -(4-chlorophenyl)- 1 -methylethyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide, N-r4-!2-!!2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]ρhenyll-4-
[5-f 1 -(4-trifluoromethoxyphenyl)- 1 -ethyl]-! 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-14-!2-!!2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[5-11 -fluoro-l-(4-trifluoromethoxyphenyl)methyl]-f 1,2,4]- oxadiazol-3-yl]benzenesulfonamide,
N-!4-!2-ϋ2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4-
!5-!l-(6-fluoronaphth-2-yl)-l-hydroxymethyl]-ll,2,41-oxadiazol-3- yl]benzenesulfonamide,
N-r4-f2-!!2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- 15- [ 1 -(6-fluoronaphth-2-yl)- 1 -ethylH 1 ,2,4]-oxadiazol-3- yl]benzenesulfonamide,
N-f4-!2-f!2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4- f5-!l -(6-fluoronaphth-2-yl)-l-methylethyn-!l,2,4]-oxadiazol-3- yl] benzenesulfonamide, N-f4-!2-ff2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyll-4-
!3-(4-trifluoromethylphenyl)-! 1,2,4] -oxadiazol-5- yl]benzenesulfonamide, and
N-!4-!2-fl2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-
[3-(4-trifluoromethoxyphenyl)-!l,2,4]-oxadiazol-5- yllbenzenesulfonamide.
16. A compound of Claim 1 having the formula Ic:
Figure imgf000102_0001
Ic
17. A method for the treatment of diabetes which comprises administering to a diabetic patient an effective amount of a compound of Claim 1.
18. A method for the treatment of obesity which comprises administering to an obese patient an effective amount of a compound of Claim 1.
19. A method for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels which comprises administering to a patient needing lower triglyceride and cholesterol levels or higher high density lipoprotein levels an effective amount of a compound of Claim 1.
20. A method for decreasing gut motility which comprises administering to a patient in need of decreased gut motility, an effective amount of a compound of Claim 1.
21. A method for reducing neurogenic inflammation of airways which comprises administering to a patient in need of reduced neurogenic inflammation, an effective amount of a compound of Claim 1.
22. A method for reducing depression which comprises administering to a depressed patient an effective amount of a compound of Claim 1.
23. A method for treating gastrointestinal disorders which comprises administering to a patient with gastrointestinal disorders an effective amount of a compound of Claim 1.
24. A composition for the treatment of diabetes or obesity or for lowering triglyceride or cholesterol levels or increasing high density lipoprotein levels or for decreasing gut motility or for reducing neurogenic inflammation or for treating depression or for treating gastrointestinal disorders which comprises an inert carrier and an effective amount of a compound of Claim 1.
25. A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.
PCT/US1997/009536 1996-06-07 1997-06-03 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY WO1997046556A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97929769A EP0906310A4 (en) 1996-06-07 1997-06-03 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
JP10500782A JP2000511903A (en) 1996-06-07 1997-06-03 Oxadiazole benzenesulfonamide as a selective beta 3 agonist for the treatment of diabetes and obesity
AU33748/97A AU712057B2 (en) 1996-06-07 1997-06-03 Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1929596P 1996-06-07 1996-06-07
US60/019,295 1996-06-07
GB9614191.6 1996-07-05
GBGB9614191.6A GB9614191D0 (en) 1996-07-05 1996-07-05 Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity

Publications (1)

Publication Number Publication Date
WO1997046556A1 true WO1997046556A1 (en) 1997-12-11

Family

ID=26309646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/009536 WO1997046556A1 (en) 1996-06-07 1997-06-03 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Country Status (5)

Country Link
EP (1) EP0906310A4 (en)
JP (1) JP2000511903A (en)
AU (1) AU712057B2 (en)
CA (1) CA2257206A1 (en)
WO (1) WO1997046556A1 (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
EP1138685A2 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Process for preparing substituted pyridines
WO2002006221A2 (en) * 2000-07-17 2002-01-24 Wyeth Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
WO2002006276A1 (en) * 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6569873B2 (en) 2000-07-17 2003-05-27 Wyeth Azolidines as beta-3 adrenergic receptor agonists
US6583140B2 (en) 2000-07-17 2003-06-24 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6660752B2 (en) 2001-04-23 2003-12-09 Bayer Pharmaceuticals Corporation 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
WO2004043443A2 (en) * 2002-11-12 2004-05-27 Nicox S.A. Drugs for sexual dysfunctions
US6780859B2 (en) 2001-09-14 2004-08-24 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
WO2005061489A1 (en) * 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7022716B2 (en) 2000-07-17 2006-04-04 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2006067532A1 (en) * 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
EP1741446A2 (en) 2000-01-21 2007-01-10 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007033266A2 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
US7202262B2 (en) 2003-04-11 2007-04-10 Ptc Therapeutics, Inc. Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
WO2008098025A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Arylsulfonamide compounds which modulate the cb2 receptor
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011016470A1 (en) * 2009-08-05 2011-02-10 第一三共株式会社 Sulfone derivative
WO2011016469A1 (en) * 2009-08-05 2011-02-10 第一三共株式会社 Amide derivative
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8048899B2 (en) 2008-09-25 2011-11-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8153814B2 (en) 2009-01-12 2012-04-10 Pfizer Limited Sulfonamide derivatives
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012117336A3 (en) * 2011-02-28 2013-01-03 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Apoptosis-inducing molecules and uses therefor
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014033343A1 (en) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
CN103827111A (en) * 2011-07-29 2014-05-28 第一三共株式会社 N-hetero-ring-substituted amide derivative
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
US8865744B1 (en) 2013-05-17 2014-10-21 Boehringer Ingelheim International Gmbh (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
US9289398B2 (en) 2006-03-30 2016-03-22 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US10517853B2 (en) 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0906310A4 *

Cited By (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743655A1 (en) 2000-01-21 2007-01-17 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
EP1741446A2 (en) 2000-01-21 2007-01-10 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
US6670480B2 (en) 2000-03-31 2003-12-30 Pfizer Inc. Process for preparing substituted pyridines
EP1138685A2 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Process for preparing substituted pyridines
US6844441B2 (en) 2000-03-31 2005-01-18 Pfizer Inc Process for preparing substituted pyridines
EP1138685A3 (en) * 2000-03-31 2003-04-02 Pfizer Products Inc. Process for preparing substituted pyridines
WO2002006276A1 (en) * 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
US6730792B2 (en) 2000-07-13 2004-05-04 Eli Lilly And Company β3 adrenergic agonists
WO2002006221A3 (en) * 2000-07-17 2002-06-13 American Home Prod Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
US7022716B2 (en) 2000-07-17 2006-04-04 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6649603B2 (en) 2000-07-17 2003-11-18 Wyeth Cyclylamine sulfonamides as β3-adrenergic receptor agonists
US6583140B2 (en) 2000-07-17 2003-06-24 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6569873B2 (en) 2000-07-17 2003-05-27 Wyeth Azolidines as beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6821991B2 (en) 2000-07-17 2004-11-23 Wyeth 2-substituted thiazolidinones as β-3 adrenergic receptor agonists
WO2002006221A2 (en) * 2000-07-17 2002-01-24 Wyeth Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US7122680B2 (en) 2000-11-10 2006-10-17 Eli Lilly And Company 3-Substituted oxindole β3 agonsists
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US6919371B2 (en) 2001-04-23 2005-07-19 Bayer Pharmaceuticals Corporation 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6660752B2 (en) 2001-04-23 2003-12-09 Bayer Pharmaceuticals Corporation 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US7087635B2 (en) 2001-08-14 2006-08-08 Eli Lilly And Company 3-substituted oxindole β3 agonists
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
US6780859B2 (en) 2001-09-14 2004-08-24 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
US7265127B2 (en) 2001-11-20 2007-09-04 Eli Lilly And Company β3 adrenergic agonists
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7253181B2 (en) 2001-11-20 2007-08-07 Eli Lilly And Company β3 adrenergic agonists
US7241772B2 (en) 2001-11-20 2007-07-10 Eli Lilly And Company β3 adrenergic agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7214697B2 (en) 2002-01-11 2007-05-08 Eli Lilly And Company 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
WO2004043443A2 (en) * 2002-11-12 2004-05-27 Nicox S.A. Drugs for sexual dysfunctions
WO2004043443A3 (en) * 2002-11-12 2004-07-15 Nicox Sa Drugs for sexual dysfunctions
US9205088B2 (en) 2003-04-11 2015-12-08 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use
US8227494B2 (en) 2003-04-11 2012-07-24 Ptc Therapeutics, Inc. Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease
US7202262B2 (en) 2003-04-11 2007-04-10 Ptc Therapeutics, Inc. Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease
US8129540B2 (en) 2003-04-11 2012-03-06 Ptc Therapeutics, Inc. Methods for the synthesis of 1,2,4-oxadiazole benzoic acid compounds
US9861617B2 (en) 2003-04-11 2018-01-09 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use
US10071081B2 (en) 2003-04-11 2018-09-11 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use
US8163782B2 (en) 2003-04-11 2012-04-24 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compositions
US8017636B2 (en) 2003-04-11 2011-09-13 Ptc Therapeutics, Inc. 1,2,4-Oxadiazole benzoic acid compositions and their use in bioassays
US7304080B2 (en) 2003-04-11 2007-12-04 Ptc Therapeutics, Inc. Substituted 1,2,4-oxadiazoles, compositions and methods of use
US7772259B2 (en) 2003-04-11 2010-08-10 Ptc Therapeutics, Inc. 1,2,4-Oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US8796322B2 (en) 2003-04-11 2014-08-05 Ptc Therapeutics, Inc. Methods for using 1,2,4-oxadiazole benzoic acid compounds
US7419991B2 (en) 2003-04-11 2008-09-02 Ptc Therapeutics, Inc. 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, compositions, and methods for the use thereof
US8486982B2 (en) 2003-04-11 2013-07-16 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acids
US8299105B2 (en) 2003-04-11 2012-10-30 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays
US8975287B2 (en) 2003-04-11 2015-03-10 Ptc Therapeutics, Inc. Methods for using 1,2,4-Oxadiazole benzoic acid compounds
US7683082B2 (en) 2003-04-11 2010-03-23 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
WO2005061489A1 (en) * 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
JP2008525417A (en) * 2004-12-24 2008-07-17 プロシディオン・リミテッド G protein-coupled receptor agonist
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
WO2006067532A1 (en) * 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
WO2007003961A3 (en) * 2005-06-30 2007-03-01 Prosidion Ltd Gpcr agonists
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JP2008545008A (en) * 2005-06-30 2008-12-11 プロシディオン・リミテッド GPCR agonist
WO2007033266A2 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US9289398B2 (en) 2006-03-30 2016-03-22 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8299111B2 (en) 2006-07-28 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8829034B2 (en) 2006-09-25 2014-09-09 Boehringer Ingerlheim International GmbH Compounds which modulate the CB2 receptor
WO2008098025A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Arylsulfonamide compounds which modulate the cb2 receptor
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8048899B2 (en) 2008-09-25 2011-11-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8372874B2 (en) 2008-09-25 2013-02-12 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8907101B2 (en) 2009-01-12 2014-12-09 Pfizer Limited Sulfonamide derivatives
US8541588B2 (en) 2009-01-12 2013-09-24 Pfizer Limited Sulfonamide derivatives
US8153814B2 (en) 2009-01-12 2012-04-10 Pfizer Limited Sulfonamide derivatives
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
CN102548977A (en) * 2009-08-05 2012-07-04 第一三共株式会社 Sulfone derivative
TWI452045B (en) * 2009-08-05 2014-09-11 Daiichi Sankyo Co Ltd Sulfone derivatives
CN102574823A (en) * 2009-08-05 2012-07-11 第一三共株式会社 Amide derivative
US8557802B2 (en) 2009-08-05 2013-10-15 Daiichi Sankyo Company, Limited Amide derivative
WO2011016469A1 (en) * 2009-08-05 2011-02-10 第一三共株式会社 Amide derivative
US8754112B2 (en) 2009-08-05 2014-06-17 Daiichi Sankyo Company, Limited Sulfone derivative
WO2011016470A1 (en) * 2009-08-05 2011-02-10 第一三共株式会社 Sulfone derivative
CN102574823B (en) * 2009-08-05 2014-09-10 第一三共株式会社 Amide derivative
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012117336A3 (en) * 2011-02-28 2013-01-03 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Apoptosis-inducing molecules and uses therefor
US9006273B2 (en) 2011-07-29 2015-04-14 Daiichi Sankyo Company, Limited N-hetero-ring-substituted amide derivative
CN103827111B (en) * 2011-07-29 2016-03-23 第一三共株式会社 N-Heterocyclically substituted amides derivative
CN103827111A (en) * 2011-07-29 2014-05-28 第一三共株式会社 N-hetero-ring-substituted amide derivative
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014033343A1 (en) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10570125B2 (en) 2013-05-17 2020-02-25 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9650370B2 (en) 2013-05-17 2017-05-16 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US11725004B2 (en) 2013-05-17 2023-08-15 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US11084810B2 (en) 2013-05-17 2021-08-10 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US10112934B2 (en) 2013-05-17 2018-10-30 Centrexion Therapeutics Corporation (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US8865744B1 (en) 2013-05-17 2014-10-21 Boehringer Ingelheim International Gmbh (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10618877B2 (en) 2014-03-06 2020-04-14 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10233161B2 (en) 2014-03-06 2019-03-19 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10517853B2 (en) 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Also Published As

Publication number Publication date
AU3374897A (en) 1998-01-05
JP2000511903A (en) 2000-09-12
CA2257206A1 (en) 1997-12-11
AU712057B2 (en) 1999-10-28
EP0906310A4 (en) 1999-09-01
EP0906310A1 (en) 1999-04-07

Similar Documents

Publication Publication Date Title
AU712057B2 (en) Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
AU728812B2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US5705515A (en) Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5451677A (en) Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
JP6861858B2 (en) SSAO inhibitor
JP3149186B2 (en) Substituted sulfonamides as selective beta-3 agents for the treatment of diabetes and obesity
US6291491B1 (en) Amide derivatives as β 3 agonists
US5541197A (en) Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US6011048A (en) Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
SK282753B6 (en) Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma
JP2008540597A (en) Substituted benzo [d] isoxazol-3-yl-amine-compounds and their use as vanilloid receptor ligands
DK2059503T3 (en) Aminopyrazole derivatives, processes for their preparation, and compositions containing these derivatives for the prevention or treatment of ischemic diseases
US6034106A (en) Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
JP5421589B2 (en) Use of 2,5-disubstituted thiazol-4-one derivatives in medicine
JP2001525398A (en) Selective β3 adrenergic agonist
GB2356196A (en) Guanidine and ethylenediamine derivatives as beta 3 agonists
MXPA99007032A (en) THIAZOLE BENZENESULFONAMIDES AS&bgr;3
CZ268199A3 (en) Thiazole benzenesulfonamides and pharmaceutical preparation containing thereof
Fisher et al. Substituted Sulfonamides as Selective β3 Agonists for the Treatment of Diabetes and Obesity
WO2006006832A1 (en) Sulfamide derivatives and pharmaceutical composition for upregulation of lipid metabolism comprising same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2257206

Country of ref document: CA

Ref country code: CA

Ref document number: 2257206

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997929769

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997929769

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1997929769

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997929769

Country of ref document: EP